[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fH1BlEEa97oRmXqNjEupHF1f_BBH45xZtEYr0dk5bhM0":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":11,"nonDrugCount":12,"topConditions":13,"upcomingReadouts":35,"phaseBuckets":86,"rows":93},"Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)",[4],517,false,168,36,257561,56,370,[14,17,20,23,26,28,30,33],{"name":15,"count":16},"Prostate Cancer",10,{"name":18,"count":19},"Esophageal Cancer",9,{"name":21,"count":22},"Sickle Cell Disease",8,{"name":24,"count":25},"Surgery",7,{"name":27,"count":25},"Colorectal Cancer",{"name":29,"count":25},"Anesthesia",{"name":31,"count":32},"Ulcerative Colitis",6,{"name":34,"count":32},"Coronary Artery Disease",[36,41,46,51,56,61,66,71,76,81],{"nctId":37,"briefTitle":38,"date":39,"intervention":40},"NCT04554771","Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy","2022-10-10","Tocilizumab 20 Mg\u002FmL Intravenous Solution",{"nctId":42,"briefTitle":43,"date":44,"intervention":45},"NCT04014530","Pembrolizumab With Ataluren in Patients With Metastatic pMMR and dMMR Colorectal Carcinoma or Metastatic dMMR Endometrial Carcinoma: the ATAPEMBRO Study","2023-06-01","Ataluren + Pembrolizumab",{"nctId":47,"briefTitle":48,"date":49,"intervention":50},"NCT03844256","A Study of Mitomycin-c\u002F Capecitabine ChemoRadiotherapy Combined With Nivolumab Monotherapy or Ipilumimab and Nivolumab, as Bladder Sparing Curative Treatment for Muscle Invasive Bladder Cancer: the CRIMI Study","2024-07","nivolumab 480mg",{"nctId":52,"briefTitle":53,"date":54,"intervention":55},"NCT03379909","Phase II Study of Oral Metformin for Intravesical Treatment of Non-muscle-invasive Bladder Cancer","2024-07-31","Metformin",{"nctId":57,"briefTitle":58,"date":59,"intervention":60},"NCT04660747","Direct Oral Anticoagulants for the Treatment of Cerebral Venous Thrombosis","2024-08","Oral anticoagulant",{"nctId":62,"briefTitle":63,"date":64,"intervention":65},"NCT05621174","The Difference in the Mechanism of Action Between Two Brands of Dexamfetamine in Adults With ADHD","2024-12-31","Dexamfetamine",{"nctId":67,"briefTitle":68,"date":69,"intervention":70},"NCT06584162","Subcutaneous Interval Lengthening of Vedolizumab for Economic Research","2025-01-01","Vedolizumab",{"nctId":72,"briefTitle":73,"date":74,"intervention":75},"NCT05984238","A Trial to Evaluate Safety, Feasibility and Efficacy of the ReCET Procedure (EMINENT-2)","2025-03-21","Semaglutide, 1.0 mg\u002FmL",{"nctId":77,"briefTitle":78,"date":79,"intervention":80},"NCT06295328","From Fungus to Virus, Investigating the Safety and Efficacy of Terbinafine in Chronic Hepatitis B Patients","2025-04-01","Terbinafine",{"nctId":82,"briefTitle":83,"date":84,"intervention":85},"NCT05804097","Does Increasing Oxygen Nurture Your Symptomatic Ischemic Ulcer Sufficiently?","2025-05-01","Hyperbaric oxygen",[87,88,89,90,91,92],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[94,119,150,168,194,221,245,271,306,398,445,477,495,513,541,559,577,606,624,649,675,704,722,753,806,828,854,872,906,930,951,977,1003,1029,1050,1068,1086,1104,1122,1145,1163,1181,1207,1225,1243,1289,1314,1339,1364,1385,1405,1430,1457,1475,1493,1514,1532,1562,1587,1612,1637,1669,1687,1705,1723,1741,1759,1777,1795,1813,1831,1856,1874,1900,1918,1943,1967,1993,2020,2044,2069,2094,2119,2152,2170,2188,2206,2224,2242,2260,2278,2303,2329,2355,2373,2397,2424,2442,2469,2495,2519,2544,2562,2584,2610,2636,2663,2688,2706,2724,2749,2767,2793,2815,2840,2872,2896,2914,2939,2965,2991,3009,3033,3058,3082,3100,3126,3151,3175,3200,3224,3248,3266,3291,3309,3333,3351,3373,3396,3419,3446,3471,3489,3507,3530,3554,3578,3596,3618,3640,3665,3690,3729,3767,3796,3828,3865,3901,3926,3958,3983,4009,4027,4045,4071,4089,4107,4131,4149,4167,4193,4211,4236,4260,4286,4309,4334,4352,4370,4394,4419,4442,4460,4488,4511,4539,4563,4589,4612,4634,4656,4680,4704,4728,4746,4764],{"intervention":70,"totalTrials":95,"cells":96},1,{"EARLY_PHASE1":97,"PHASE1":100,"PHASE2":102,"PHASE3":104,"PHASE4":106,"NA":117},{"trials":98,"activeCount":99},[],0,{"trials":101,"activeCount":99},[],{"trials":103,"activeCount":99},[],{"trials":105,"activeCount":99},[],{"trials":107,"activeCount":95,"soonestReadout":69},[108],{"nctId":67,"briefTitle":68,"status":109,"phases":110,"primaryCompletion":69,"completion":111,"start":112,"enrollment":113,"conditions":114,"interventions":116},"RECRUITING",[91],"2026-02-01","2023-02-09",40,[115],"Inflammatory Bowel Diseases",[70],{"trials":118,"activeCount":99},[],{"intervention":120,"totalTrials":95,"cells":121},"Rifaximin 550 milligram Oral Tablet [XIFAXAN]",{"EARLY_PHASE1":122,"PHASE1":124,"PHASE2":126,"PHASE3":128,"PHASE4":130,"NA":148},{"trials":123,"activeCount":99},[],{"trials":125,"activeCount":99},[],{"trials":127,"activeCount":99},[],{"trials":129,"activeCount":99},[],{"trials":131,"activeCount":95,"soonestReadout":136},[132],{"nctId":133,"briefTitle":134,"status":109,"phases":135,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":140,"interventions":146},"NCT04073290","Prevention of Post-TIPS Hepatic Encephalopathy by Administration of Rifaximin and Lactulose",[91],"2026-09-30","2026-12-31","2020-01-21",238,[141,142,143,144,145],"Hepatic Encephalopathy","Cirrhosis, Liver","Portal Hypertension","Liver Diseases","Pathological Processes",[120,147],"Lactulose 667 milligram\u002Fmilliliter Oral Solution",{"trials":149,"activeCount":99},[],{"intervention":147,"totalTrials":95,"cells":151},{"EARLY_PHASE1":152,"PHASE1":154,"PHASE2":156,"PHASE3":158,"PHASE4":160,"NA":166},{"trials":153,"activeCount":99},[],{"trials":155,"activeCount":99},[],{"trials":157,"activeCount":99},[],{"trials":159,"activeCount":99},[],{"trials":161,"activeCount":95,"soonestReadout":136},[162],{"nctId":133,"briefTitle":134,"status":109,"phases":163,"primaryCompletion":136,"completion":137,"start":138,"enrollment":139,"conditions":164,"interventions":165},[91],[141,142,143,144,145],[120,147],{"trials":167,"activeCount":99},[],{"intervention":169,"totalTrials":95,"cells":170},"Botulinum toxin type A",{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":192},{"trials":172,"activeCount":99},[],{"trials":174,"activeCount":99},[],{"trials":176,"activeCount":99},[],{"trials":178,"activeCount":99},[],{"trials":180,"activeCount":95,"soonestReadout":186},[181],{"nctId":182,"briefTitle":183,"status":184,"phases":185,"primaryCompletion":186,"completion":187,"start":69,"enrollment":188,"conditions":189,"interventions":191},"NCT06448676","Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides","NOT_YET_RECRUITING",[91],"2025-10-01","2025-11-01",200,[190],"Wrinkle",[169],{"trials":193,"activeCount":99},[],{"intervention":195,"totalTrials":95,"cells":196},"Reduced noradrenaline use",{"EARLY_PHASE1":197,"PHASE1":199,"PHASE2":201,"PHASE3":203,"PHASE4":205,"NA":219},{"trials":198,"activeCount":99},[],{"trials":200,"activeCount":99},[],{"trials":202,"activeCount":99},[],{"trials":204,"activeCount":99},[],{"trials":206,"activeCount":95,"soonestReadout":211},[207],{"nctId":208,"briefTitle":209,"status":109,"phases":210,"primaryCompletion":211,"completion":212,"start":213,"enrollment":214,"conditions":215,"interventions":218},"NCT05168462","Clinical Outcome and Cost-effectiveness of Reduced Noradrenaline by Using a Lower Blood Pressure Target in Patients With Cardiogenic Shock From Acute Myocardial Infarction",[91],"2027-04-01","2028-04-01","2022-10-01",776,[216,217],"Cardiogenic Shock","Myocardial Infarction",[195],{"trials":220,"activeCount":99},[],{"intervention":85,"totalTrials":95,"cells":222},{"EARLY_PHASE1":223,"PHASE1":225,"PHASE2":227,"PHASE3":229,"PHASE4":231,"NA":243},{"trials":224,"activeCount":99},[],{"trials":226,"activeCount":99},[],{"trials":228,"activeCount":99},[],{"trials":230,"activeCount":99},[],{"trials":232,"activeCount":95,"soonestReadout":84},[233],{"nctId":82,"briefTitle":83,"status":234,"phases":235,"primaryCompletion":84,"completion":84,"start":236,"enrollment":237,"conditions":238,"interventions":242},"ACTIVE_NOT_RECRUITING",[91],"2021-10-08",30,[239,240,241],"Peripheral Vascular Disease","Diabetic Foot Ulcer","Amputation",[85],{"trials":244,"activeCount":99},[],{"intervention":246,"totalTrials":95,"cells":247},"Dupilumab",{"EARLY_PHASE1":248,"PHASE1":250,"PHASE2":252,"PHASE3":254,"PHASE4":256,"NA":269},{"trials":249,"activeCount":99},[],{"trials":251,"activeCount":99},[],{"trials":253,"activeCount":99},[],{"trials":255,"activeCount":99},[],{"trials":257,"activeCount":95,"soonestReadout":186},[258],{"nctId":259,"briefTitle":260,"status":109,"phases":261,"primaryCompletion":186,"completion":262,"start":263,"enrollment":264,"conditions":265,"interventions":268},"NCT06004986","DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema",[91],"2025-12-31","2023-08-14",216,[266,267],"Atopic Dermatitis","Atopic Dermatitis Eczema",[246],{"trials":270,"activeCount":99},[],{"intervention":272,"totalTrials":95,"cells":273},"HOP bundle",{"EARLY_PHASE1":274,"PHASE1":276,"PHASE2":278,"PHASE3":280,"PHASE4":282,"NA":304},{"trials":275,"activeCount":99},[],{"trials":277,"activeCount":99},[],{"trials":279,"activeCount":99},[],{"trials":281,"activeCount":99},[],{"trials":283,"activeCount":95,"soonestReadout":288},[284],{"nctId":285,"briefTitle":286,"status":109,"phases":287,"primaryCompletion":288,"completion":289,"start":290,"enrollment":291,"conditions":292,"interventions":303},"NCT07262957","Preventing Postoperative Complications in Patients Undergoing High-risk Pancreatoduodenectomy With a Bundle Approach Including Hydrocortisone, Octreotide, and the Teres Ligament Patch (PANENCA)",[91],"2027-09-01","2027-12-01","2025-09-01",400,[293,294,295,296,297,298,299,300,301,302],"Pancreas Head Cancer","Pancreas Adenocarcinoma","IPMN, Pancreatic","Cholangio Carcinoma","Ampulla of Vater Adenocarcinoma","PDAC - Pancreatic Ductal Adenocarcinoma","Duodenal Carcinoma","Mucinous Cystic Neoplasm","Neuro Endocrine Tumours","Pancreatitis",[272],{"trials":305,"activeCount":99},[],{"intervention":307,"totalTrials":32,"cells":308},"Carboplatin",{"EARLY_PHASE1":309,"PHASE1":311,"PHASE2":313,"PHASE3":368,"PHASE4":382,"NA":384},{"trials":310,"activeCount":99},[],{"trials":312,"activeCount":99},[],{"trials":314,"activeCount":367,"soonestReadout":39},[315,330,343,357],{"nctId":316,"briefTitle":317,"status":234,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":324},"NCT03764553","Liposomal iRInotecan, Carboplatin or oXaliplatin for Esophagogastric Cancer",[89],"2025-07-31","2026-07-01","2019-05-01",320,[18],[325,307,326,327,328,329],"Liposomal Irinotecan","Capecitabine","Oxaliplatin","5-fluorouracil","Leucovorin",{"nctId":331,"briefTitle":332,"status":333,"phases":334,"primaryCompletion":335,"completion":335,"start":336,"enrollment":113,"conditions":337,"interventions":340},"NCT03087864","PDL-1 Targeting in Resectable Oesophageal Cancer","COMPLETED",[89],"2019-07-01","2017-06-28",[338,339],"Esophageal Cancer, Stage II","Esophageal Cancer Stage III",[341,307,342],"Atezolizumab","Paclitaxel",{"nctId":344,"briefTitle":345,"status":333,"phases":346,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":351,"interventions":355},"NCT01077999","Chemoradiation and Panitumumab for Esophageal Cancer",[89],"2011-02","2012-04","2010-01",78,[352,353,18,354],"Squamous Cell Carcinoma","Adenocarcinoma","Gastro-esophageal Junction Cancer",[307,342,356],"panitumumab",{"nctId":37,"briefTitle":38,"status":234,"phases":358,"primaryCompletion":39,"completion":359,"start":360,"enrollment":361,"conditions":362,"interventions":366},[89],"2028-04-10","2021-01-27",41,[363,364,365],"Esophageal Adenocarcinoma","Oesophageal Adenocarcinoma","Resectable Carcinoma",[40,342,307],2,{"trials":369,"activeCount":95,"soonestReadout":374},[370],{"nctId":371,"briefTitle":372,"status":109,"phases":373,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":378,"interventions":379},"NCT05188313","TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer",[90],"2027-07","2037-02","2022-03-09",376,[18,363],[380,381,342,307],"Trastuzumab","Pertuzumab",{"trials":383,"activeCount":99},[],{"trials":385,"activeCount":95,"soonestReadout":290},[386],{"nctId":387,"briefTitle":388,"status":109,"phases":389,"primaryCompletion":290,"completion":390,"start":391,"enrollment":392,"conditions":393,"interventions":396},"NCT04481256","TGF-β And PDL-1 Inhibition in Esophageal Squamous Cell Carcinoma Combined With Chemoradiation TheRapY",[92],"2030-09-01","2020-11-11",49,[394,395],"Carcinoma, Squamous Cell","Oesophageal Cancer",[397,342,307],"Bintrafusp alfa",{"intervention":342,"totalTrials":32,"cells":399},{"EARLY_PHASE1":400,"PHASE1":402,"PHASE2":404,"PHASE3":431,"PHASE4":437,"NA":439},{"trials":401,"activeCount":99},[],{"trials":403,"activeCount":99},[],{"trials":405,"activeCount":95,"soonestReadout":39},[406,410,414,427],{"nctId":331,"briefTitle":332,"status":333,"phases":407,"primaryCompletion":335,"completion":335,"start":336,"enrollment":113,"conditions":408,"interventions":409},[89],[338,339],[341,307,342],{"nctId":344,"briefTitle":345,"status":333,"phases":411,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":412,"interventions":413},[89],[352,353,18,354],[307,342,356],{"nctId":415,"briefTitle":416,"status":333,"phases":417,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":421,"interventions":425},"NCT02406170","Regorafenib in Combination With Paclitaxel in Advanced Oesophagogastric Carcinoma",[88,89],"2019-10","2015-04",47,[422,423,424],"Esophageal Neoplasms","Stomach Neoplasms","Neoplasm Metastasis",[426,342],"Regorafenib",{"nctId":37,"briefTitle":38,"status":234,"phases":428,"primaryCompletion":39,"completion":359,"start":360,"enrollment":361,"conditions":429,"interventions":430},[89],[363,364,365],[40,342,307],{"trials":432,"activeCount":95,"soonestReadout":374},[433],{"nctId":371,"briefTitle":372,"status":109,"phases":434,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":435,"interventions":436},[90],[18,363],[380,381,342,307],{"trials":438,"activeCount":99},[],{"trials":440,"activeCount":95,"soonestReadout":290},[441],{"nctId":387,"briefTitle":388,"status":109,"phases":442,"primaryCompletion":290,"completion":390,"start":391,"enrollment":392,"conditions":443,"interventions":444},[92],[394,395],[397,342,307],{"intervention":446,"totalTrials":95,"cells":447},"Chemotherapy",{"EARLY_PHASE1":448,"PHASE1":450,"PHASE2":452,"PHASE3":454,"PHASE4":473,"NA":475},{"trials":449,"activeCount":99},[],{"trials":451,"activeCount":99},[],{"trials":453,"activeCount":99},[],{"trials":455,"activeCount":95,"soonestReadout":460},[456],{"nctId":457,"briefTitle":458,"status":109,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":464,"interventions":470},"NCT07000253","Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma",[89,90],"2031-06","2034-01","2026-04-29",290,[18,465,466,467,468,469],"Gastric (Stomach) Cancer","Gastric Adenocarcinoma","Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma","Esophageal Carcinoma","Gastric (Cardia, Body) Cancer",[446,471,472],"Targeted Systemic Therapy","Immunotherapy",{"trials":474,"activeCount":99},[],{"trials":476,"activeCount":99},[],{"intervention":471,"totalTrials":95,"cells":478},{"EARLY_PHASE1":479,"PHASE1":481,"PHASE2":483,"PHASE3":485,"PHASE4":491,"NA":493},{"trials":480,"activeCount":99},[],{"trials":482,"activeCount":99},[],{"trials":484,"activeCount":99},[],{"trials":486,"activeCount":95,"soonestReadout":460},[487],{"nctId":457,"briefTitle":458,"status":109,"phases":488,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":489,"interventions":490},[89,90],[18,465,466,467,468,469],[446,471,472],{"trials":492,"activeCount":99},[],{"trials":494,"activeCount":99},[],{"intervention":472,"totalTrials":95,"cells":496},{"EARLY_PHASE1":497,"PHASE1":499,"PHASE2":501,"PHASE3":503,"PHASE4":509,"NA":511},{"trials":498,"activeCount":99},[],{"trials":500,"activeCount":99},[],{"trials":502,"activeCount":99},[],{"trials":504,"activeCount":95,"soonestReadout":460},[505],{"nctId":457,"briefTitle":458,"status":109,"phases":506,"primaryCompletion":460,"completion":461,"start":462,"enrollment":463,"conditions":507,"interventions":508},[89,90],[18,465,466,467,468,469],[446,471,472],{"trials":510,"activeCount":99},[],{"trials":512,"activeCount":99},[],{"intervention":514,"totalTrials":95,"cells":515},"Fluvoxamine",{"EARLY_PHASE1":516,"PHASE1":518,"PHASE2":520,"PHASE3":522,"PHASE4":537,"NA":539},{"trials":517,"activeCount":99},[],{"trials":519,"activeCount":99},[],{"trials":521,"activeCount":99},[],{"trials":523,"activeCount":95,"soonestReadout":528},[524],{"nctId":525,"briefTitle":526,"status":184,"phases":527,"primaryCompletion":528,"completion":529,"start":530,"enrollment":531,"conditions":532,"interventions":536},"NCT07359482","sElective Serotonin reuPtake inhibitoRs In posT-covid After COVID-19",[90],"2027-03-01","2028-05-01","2026-03-01",160,[533,534,535],"Post-COVID","POST-Covid 19","Post-COVID Conditions",[514],{"trials":538,"activeCount":99},[],{"trials":540,"activeCount":99},[],{"intervention":380,"totalTrials":95,"cells":542},{"EARLY_PHASE1":543,"PHASE1":545,"PHASE2":547,"PHASE3":549,"PHASE4":555,"NA":557},{"trials":544,"activeCount":99},[],{"trials":546,"activeCount":99},[],{"trials":548,"activeCount":99},[],{"trials":550,"activeCount":95,"soonestReadout":374},[551],{"nctId":371,"briefTitle":372,"status":109,"phases":552,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":553,"interventions":554},[90],[18,363],[380,381,342,307],{"trials":556,"activeCount":99},[],{"trials":558,"activeCount":99},[],{"intervention":381,"totalTrials":95,"cells":560},{"EARLY_PHASE1":561,"PHASE1":563,"PHASE2":565,"PHASE3":567,"PHASE4":573,"NA":575},{"trials":562,"activeCount":99},[],{"trials":564,"activeCount":99},[],{"trials":566,"activeCount":99},[],{"trials":568,"activeCount":95,"soonestReadout":374},[569],{"nctId":371,"briefTitle":372,"status":109,"phases":570,"primaryCompletion":374,"completion":375,"start":376,"enrollment":377,"conditions":571,"interventions":572},[90],[18,363],[380,381,342,307],{"trials":574,"activeCount":99},[],{"trials":576,"activeCount":99},[],{"intervention":578,"totalTrials":95,"cells":579},"Infliximab subcutaneous",{"EARLY_PHASE1":580,"PHASE1":582,"PHASE2":584,"PHASE3":586,"PHASE4":602,"NA":604},{"trials":581,"activeCount":99},[],{"trials":583,"activeCount":99},[],{"trials":585,"activeCount":99},[],{"trials":587,"activeCount":95,"soonestReadout":592},[588],{"nctId":589,"briefTitle":590,"status":109,"phases":591,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":596,"interventions":600},"NCT06059989","InDuctIon TREatment with SubCuTaneous Infliximab for Crohn's Disease",[90],"2025-06","2025-12","2021-11-25",158,[597,598,599],"Inflammatory Disease","Disease Crohn","Bowel Disease",[578,601],"Immunosuppressive Agents",{"trials":603,"activeCount":99},[],{"trials":605,"activeCount":99},[],{"intervention":601,"totalTrials":95,"cells":607},{"EARLY_PHASE1":608,"PHASE1":610,"PHASE2":612,"PHASE3":614,"PHASE4":620,"NA":622},{"trials":609,"activeCount":99},[],{"trials":611,"activeCount":99},[],{"trials":613,"activeCount":99},[],{"trials":615,"activeCount":95,"soonestReadout":592},[616],{"nctId":589,"briefTitle":590,"status":109,"phases":617,"primaryCompletion":592,"completion":593,"start":594,"enrollment":595,"conditions":618,"interventions":619},[90],[597,598,599],[578,601],{"trials":621,"activeCount":99},[],{"trials":623,"activeCount":99},[],{"intervention":625,"totalTrials":95,"cells":626},"Ziltivekimab",{"EARLY_PHASE1":627,"PHASE1":629,"PHASE2":631,"PHASE3":633,"PHASE4":645,"NA":647},{"trials":628,"activeCount":99},[],{"trials":630,"activeCount":99},[],{"trials":632,"activeCount":99},[],{"trials":634,"activeCount":95,"soonestReadout":320},[635],{"nctId":636,"briefTitle":637,"status":109,"phases":638,"primaryCompletion":320,"completion":639,"start":640,"enrollment":113,"conditions":641,"interventions":644},"NCT06263244","Specifying the Anti-inflammatory Effects of Ziltivekimab",[90],"2026-10-01","2024-05-03",[642,643],"Atherosclerosis","Inflammation",[625],{"trials":646,"activeCount":99},[],{"trials":648,"activeCount":99},[],{"intervention":650,"totalTrials":95,"cells":651},"Tranexamic Acid 500Mg",{"EARLY_PHASE1":652,"PHASE1":654,"PHASE2":656,"PHASE3":658,"PHASE4":671,"NA":673},{"trials":653,"activeCount":99},[],{"trials":655,"activeCount":99},[],{"trials":657,"activeCount":99},[],{"trials":659,"activeCount":95,"soonestReadout":664},[660],{"nctId":661,"briefTitle":662,"status":109,"phases":663,"primaryCompletion":664,"completion":665,"start":666,"enrollment":667,"conditions":668,"interventions":670},"NCT03582293","Tranexamic Acid to Prevent OpeRation in Chronic Subdural Hematoma",[90],"2029-04-30","2029-10-30","2018-06-19",554,[669],"Hematoma, Subdural, Chronic",[650],{"trials":672,"activeCount":99},[],{"trials":674,"activeCount":99},[],{"intervention":676,"totalTrials":95,"cells":677},"Fentanyl Citrate",{"EARLY_PHASE1":678,"PHASE1":680,"PHASE2":682,"PHASE3":684,"PHASE4":700,"NA":702},{"trials":679,"activeCount":99},[],{"trials":681,"activeCount":99},[],{"trials":683,"activeCount":99},[],{"trials":685,"activeCount":95,"soonestReadout":690},[686],{"nctId":687,"briefTitle":688,"status":109,"phases":689,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":693,"interventions":699},"NCT06051227","Fentanyl or Esketamine for Traumatic PAIN (FORE-PAIN) Trial",[90],"2026-03","2024-01-11",608,[694,695,696,697,698],"Acute Pain Due to Trauma","Analgesia","Fentanyl","Esketamine","Emergency Medical Services",[676,697],{"trials":701,"activeCount":99},[],{"trials":703,"activeCount":99},[],{"intervention":697,"totalTrials":95,"cells":705},{"EARLY_PHASE1":706,"PHASE1":708,"PHASE2":710,"PHASE3":712,"PHASE4":718,"NA":720},{"trials":707,"activeCount":99},[],{"trials":709,"activeCount":99},[],{"trials":711,"activeCount":99},[],{"trials":713,"activeCount":95,"soonestReadout":690},[714],{"nctId":687,"briefTitle":688,"status":109,"phases":715,"primaryCompletion":690,"completion":690,"start":691,"enrollment":692,"conditions":716,"interventions":717},[90],[694,695,696,697,698],[676,697],{"trials":719,"activeCount":99},[],{"trials":721,"activeCount":99},[],{"intervention":723,"totalTrials":95,"cells":724},"Immune Globulin Intravenous",{"EARLY_PHASE1":725,"PHASE1":727,"PHASE2":729,"PHASE3":731,"PHASE4":749,"NA":751},{"trials":726,"activeCount":99},[],{"trials":728,"activeCount":99},[],{"trials":730,"activeCount":99},[],{"trials":732,"activeCount":95,"soonestReadout":737},[733],{"nctId":734,"briefTitle":735,"status":234,"phases":736,"primaryCompletion":737,"completion":738,"start":739,"enrollment":740,"conditions":741,"interventions":748},"NCT05832034","Add-on Intravenous Immunoglobulins in Early Myositis",[89,90],"2025-09-25","2026-07","2021-09-13",44,[742,743,744,745,746,747],"Inflammatory Myopathy, Idiopathic","Dermatomyositis","Antisynthetase Syndrome","Immune-Mediated Necrotizing Myopathy","Polymyositis","Myositis",[723],{"trials":750,"activeCount":99},[],{"trials":752,"activeCount":99},[],{"intervention":326,"totalTrials":754,"cells":755},4,{"EARLY_PHASE1":756,"PHASE1":758,"PHASE2":760,"PHASE3":800,"PHASE4":802,"NA":804},{"trials":757,"activeCount":99},[],{"trials":759,"activeCount":99},[],{"trials":761,"activeCount":367,"soonestReadout":84},[762,775,779,789],{"nctId":763,"briefTitle":764,"status":765,"phases":766,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":771,"interventions":773},"NCT01079702","Everolimus and Capecitabine in Patients With Advanced Malignancy","UNKNOWN",[88,89],"2010-04","2011-01","2008-04",35,[772],"Advanced Malignancies",[774,326],"Everolimus",{"nctId":316,"briefTitle":317,"status":234,"phases":776,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":777,"interventions":778},[89],[18],[325,307,326,327,328,329],{"nctId":780,"briefTitle":781,"status":109,"phases":782,"primaryCompletion":84,"completion":783,"start":784,"enrollment":785,"conditions":786,"interventions":787},"NCT05177133","Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)",[89],"2029-11-04","2021-11-05",25,[466,363],[326,327,788],"Retifanlimab",{"nctId":790,"briefTitle":791,"status":333,"phases":792,"primaryCompletion":793,"completion":794,"start":795,"enrollment":770,"conditions":796,"interventions":798},"NCT01077986","Everolimus, Cetuximab and Capecitabine in Patients With Metastatic Pancreatic Cancer",[88,89],"2010-08","2011-08","2009-08",[797],"Metastatic Pancreatic Cancer",[326,799,774],"Cetuximab",{"trials":801,"activeCount":99},[],{"trials":803,"activeCount":99},[],{"trials":805,"activeCount":99},[],{"intervention":327,"totalTrials":367,"cells":807},{"EARLY_PHASE1":808,"PHASE1":810,"PHASE2":812,"PHASE3":822,"PHASE4":824,"NA":826},{"trials":809,"activeCount":99},[],{"trials":811,"activeCount":99},[],{"trials":813,"activeCount":367,"soonestReadout":84},[814,818],{"nctId":316,"briefTitle":317,"status":234,"phases":815,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":816,"interventions":817},[89],[18],[325,307,326,327,328,329],{"nctId":780,"briefTitle":781,"status":109,"phases":819,"primaryCompletion":84,"completion":783,"start":784,"enrollment":785,"conditions":820,"interventions":821},[89],[466,363],[326,327,788],{"trials":823,"activeCount":99},[],{"trials":825,"activeCount":99},[],{"trials":827,"activeCount":99},[],{"intervention":829,"totalTrials":95,"cells":830},"Flecainide",{"EARLY_PHASE1":831,"PHASE1":833,"PHASE2":835,"PHASE3":848,"PHASE4":850,"NA":852},{"trials":832,"activeCount":99},[],{"trials":834,"activeCount":99},[],{"trials":836,"activeCount":95,"soonestReadout":841},[837],{"nctId":838,"briefTitle":839,"status":184,"phases":840,"primaryCompletion":841,"completion":841,"start":842,"enrollment":16,"conditions":843,"interventions":846},"NCT06205550","N-of-1 in ATS and MEPPC",[89],"2025-10","2025-03",[844,845],"Andersen Tawil Syndrome","Multifocal Ectopic Purkinje-related Premature Contractions",[829,847],"Flecainide + beta-blocker",{"trials":849,"activeCount":99},[],{"trials":851,"activeCount":99},[],{"trials":853,"activeCount":99},[],{"intervention":847,"totalTrials":95,"cells":855},{"EARLY_PHASE1":856,"PHASE1":858,"PHASE2":860,"PHASE3":866,"PHASE4":868,"NA":870},{"trials":857,"activeCount":99},[],{"trials":859,"activeCount":99},[],{"trials":861,"activeCount":95,"soonestReadout":841},[862],{"nctId":838,"briefTitle":839,"status":184,"phases":863,"primaryCompletion":841,"completion":841,"start":842,"enrollment":16,"conditions":864,"interventions":865},[89],[844,845],[829,847],{"trials":867,"activeCount":99},[],{"trials":869,"activeCount":99},[],{"trials":871,"activeCount":99},[],{"intervention":873,"totalTrials":95,"cells":874},"Lyophilized fecal microbiota transplantation",{"EARLY_PHASE1":875,"PHASE1":877,"PHASE2":879,"PHASE3":900,"PHASE4":902,"NA":904},{"trials":876,"activeCount":99},[],{"trials":878,"activeCount":99},[],{"trials":880,"activeCount":95,"soonestReadout":885},[881],{"nctId":882,"briefTitle":883,"status":109,"phases":884,"primaryCompletion":885,"completion":886,"start":887,"enrollment":888,"conditions":889,"interventions":899},"NCT05821010","Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis",[89],"2026-02-20","2026-08-20","2023-03-17",48,[890,891,892,893,894,895,896,897,898],"Non Alcoholic Steatohepatitis","Non-Alcoholic Fatty Liver Disease","Fecal Microbiota Transplantation","FMT","Prebiotics","Probiotics","Microbiome","Intestinal Microbiome","Gut Microbiome",[873],{"trials":901,"activeCount":99},[],{"trials":903,"activeCount":99},[],{"trials":905,"activeCount":99},[],{"intervention":907,"totalTrials":95,"cells":908},"Icosapent ethyl",{"EARLY_PHASE1":909,"PHASE1":911,"PHASE2":913,"PHASE3":924,"PHASE4":926,"NA":928},{"trials":910,"activeCount":99},[],{"trials":912,"activeCount":99},[],{"trials":914,"activeCount":95,"soonestReadout":320},[915],{"nctId":916,"briefTitle":917,"status":234,"phases":918,"primaryCompletion":320,"completion":919,"start":44,"enrollment":920,"conditions":921,"interventions":923},"NCT06466278","IcoSApent ethyL to Slow Down Aortic VAlve Stenosis proGrEssion",[89],"2026-12-01",110,[922],"Aortic Valve Stenosis",[907],{"trials":925,"activeCount":99},[],{"trials":927,"activeCount":99},[],{"trials":929,"activeCount":99},[],{"intervention":45,"totalTrials":95,"cells":931},{"EARLY_PHASE1":932,"PHASE1":934,"PHASE2":936,"PHASE3":945,"PHASE4":947,"NA":949},{"trials":933,"activeCount":99},[],{"trials":935,"activeCount":99},[],{"trials":937,"activeCount":95,"soonestReadout":44},[938],{"nctId":42,"briefTitle":43,"status":109,"phases":939,"primaryCompletion":44,"completion":940,"start":941,"enrollment":420,"conditions":942,"interventions":944},[88,89],"2023-08-01","2019-08-01",[27,943],"Endometrium Cancer",[45],{"trials":946,"activeCount":99},[],{"trials":948,"activeCount":99},[],{"trials":950,"activeCount":99},[],{"intervention":952,"totalTrials":95,"cells":953},"Omeprazole 40 MG",{"EARLY_PHASE1":954,"PHASE1":956,"PHASE2":958,"PHASE3":971,"PHASE4":973,"NA":975},{"trials":955,"activeCount":99},[],{"trials":957,"activeCount":99},[],{"trials":959,"activeCount":95,"soonestReadout":964},[960],{"nctId":961,"briefTitle":962,"status":109,"phases":963,"primaryCompletion":964,"completion":965,"start":966,"enrollment":967,"conditions":968,"interventions":970},"NCT06539494","Luminal Fructose Kinetics (MARTINI Study)",[89],"2026-01","2026-04","2024-07-01",22,[969],"MASLD",[952],{"trials":972,"activeCount":99},[],{"trials":974,"activeCount":99},[],{"trials":976,"activeCount":99},[],{"intervention":978,"totalTrials":95,"cells":979},"Hyperbaric Oxygen Therapy",{"EARLY_PHASE1":980,"PHASE1":982,"PHASE2":984,"PHASE3":997,"PHASE4":999,"NA":1001},{"trials":981,"activeCount":99},[],{"trials":983,"activeCount":99},[],{"trials":985,"activeCount":95,"soonestReadout":990},[986],{"nctId":987,"briefTitle":988,"status":184,"phases":989,"primaryCompletion":990,"completion":990,"start":991,"enrollment":992,"conditions":993,"interventions":996},"NCT07535164","Hyperbaric Oxygen Therapy as Adjunctive Treatment for Fracture-Related Infection",[89],"2028-08","2026-08",50,[994,995],"Fracture Related Infection","Hyperbaric Oxygenation",[978],{"trials":998,"activeCount":99},[],{"trials":1000,"activeCount":99},[],{"trials":1002,"activeCount":99},[],{"intervention":1004,"totalTrials":95,"cells":1005},"Nadroparin Injectable Product",{"EARLY_PHASE1":1006,"PHASE1":1008,"PHASE2":1010,"PHASE3":1023,"PHASE4":1025,"NA":1027},{"trials":1007,"activeCount":99},[],{"trials":1009,"activeCount":99},[],{"trials":1011,"activeCount":95,"soonestReadout":1016},[1012],{"nctId":1013,"briefTitle":1014,"status":109,"phases":1015,"primaryCompletion":1016,"completion":211,"start":1017,"enrollment":1018,"conditions":1019,"interventions":1022},"NCT04507178","Improving Outcome in Subarachnoid Hemorrhage wIth Nadroparine",[89],"2026-08-01","2022-02-02",100,[1020,1021],"Aneurysmal Subarachnoid Hemorrhage","Delayed Cerebral Ischemia",[1004],{"trials":1024,"activeCount":99},[],{"trials":1026,"activeCount":99},[],{"trials":1028,"activeCount":99},[],{"intervention":80,"totalTrials":95,"cells":1030},{"EARLY_PHASE1":1031,"PHASE1":1033,"PHASE2":1035,"PHASE3":1044,"PHASE4":1046,"NA":1048},{"trials":1032,"activeCount":99},[],{"trials":1034,"activeCount":99},[],{"trials":1036,"activeCount":95,"soonestReadout":79},[1037],{"nctId":77,"briefTitle":78,"status":109,"phases":1038,"primaryCompletion":79,"completion":79,"start":1039,"enrollment":9,"conditions":1040,"interventions":1042},[88,89],"2022-04-13",[1041],"Chronic Hepatitis b",[80,1043],"Tenofovir",{"trials":1045,"activeCount":99},[],{"trials":1047,"activeCount":99},[],{"trials":1049,"activeCount":99},[],{"intervention":1043,"totalTrials":95,"cells":1051},{"EARLY_PHASE1":1052,"PHASE1":1054,"PHASE2":1056,"PHASE3":1062,"PHASE4":1064,"NA":1066},{"trials":1053,"activeCount":99},[],{"trials":1055,"activeCount":99},[],{"trials":1057,"activeCount":95,"soonestReadout":79},[1058],{"nctId":77,"briefTitle":78,"status":109,"phases":1059,"primaryCompletion":79,"completion":79,"start":1039,"enrollment":9,"conditions":1060,"interventions":1061},[88,89],[1041],[80,1043],{"trials":1063,"activeCount":99},[],{"trials":1065,"activeCount":99},[],{"trials":1067,"activeCount":99},[],{"intervention":325,"totalTrials":95,"cells":1069},{"EARLY_PHASE1":1070,"PHASE1":1072,"PHASE2":1074,"PHASE3":1080,"PHASE4":1082,"NA":1084},{"trials":1071,"activeCount":99},[],{"trials":1073,"activeCount":99},[],{"trials":1075,"activeCount":95,"soonestReadout":319},[1076],{"nctId":316,"briefTitle":317,"status":234,"phases":1077,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":1078,"interventions":1079},[89],[18],[325,307,326,327,328,329],{"trials":1081,"activeCount":99},[],{"trials":1083,"activeCount":99},[],{"trials":1085,"activeCount":99},[],{"intervention":328,"totalTrials":95,"cells":1087},{"EARLY_PHASE1":1088,"PHASE1":1090,"PHASE2":1092,"PHASE3":1098,"PHASE4":1100,"NA":1102},{"trials":1089,"activeCount":99},[],{"trials":1091,"activeCount":99},[],{"trials":1093,"activeCount":95,"soonestReadout":319},[1094],{"nctId":316,"briefTitle":317,"status":234,"phases":1095,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":1096,"interventions":1097},[89],[18],[325,307,326,327,328,329],{"trials":1099,"activeCount":99},[],{"trials":1101,"activeCount":99},[],{"trials":1103,"activeCount":99},[],{"intervention":329,"totalTrials":95,"cells":1105},{"EARLY_PHASE1":1106,"PHASE1":1108,"PHASE2":1110,"PHASE3":1116,"PHASE4":1118,"NA":1120},{"trials":1107,"activeCount":99},[],{"trials":1109,"activeCount":99},[],{"trials":1111,"activeCount":95,"soonestReadout":319},[1112],{"nctId":316,"briefTitle":317,"status":234,"phases":1113,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":1114,"interventions":1115},[89],[18],[325,307,326,327,328,329],{"trials":1117,"activeCount":99},[],{"trials":1119,"activeCount":99},[],{"trials":1121,"activeCount":99},[],{"intervention":50,"totalTrials":95,"cells":1123},{"EARLY_PHASE1":1124,"PHASE1":1126,"PHASE2":1128,"PHASE3":1139,"PHASE4":1141,"NA":1143},{"trials":1125,"activeCount":99},[],{"trials":1127,"activeCount":99},[],{"trials":1129,"activeCount":95,"soonestReadout":49},[1130],{"nctId":47,"briefTitle":48,"status":109,"phases":1131,"primaryCompletion":49,"completion":738,"start":1132,"enrollment":992,"conditions":1133,"interventions":1136},[88,89],"2019-01-07",[1134,1135],"Urinary Bladder Cancer","Invasive Bladder Cancer",[50,1137,1138],"nivolumab 3mg\u002Fkg, ipilimumab 1mg\u002Fkg","nivolumab 1mg\u002Fkg, ipilimumab 3mg\u002Fkg",{"trials":1140,"activeCount":99},[],{"trials":1142,"activeCount":99},[],{"trials":1144,"activeCount":99},[],{"intervention":1137,"totalTrials":95,"cells":1146},{"EARLY_PHASE1":1147,"PHASE1":1149,"PHASE2":1151,"PHASE3":1157,"PHASE4":1159,"NA":1161},{"trials":1148,"activeCount":99},[],{"trials":1150,"activeCount":99},[],{"trials":1152,"activeCount":95,"soonestReadout":49},[1153],{"nctId":47,"briefTitle":48,"status":109,"phases":1154,"primaryCompletion":49,"completion":738,"start":1132,"enrollment":992,"conditions":1155,"interventions":1156},[88,89],[1134,1135],[50,1137,1138],{"trials":1158,"activeCount":99},[],{"trials":1160,"activeCount":99},[],{"trials":1162,"activeCount":99},[],{"intervention":1138,"totalTrials":95,"cells":1164},{"EARLY_PHASE1":1165,"PHASE1":1167,"PHASE2":1169,"PHASE3":1175,"PHASE4":1177,"NA":1179},{"trials":1166,"activeCount":99},[],{"trials":1168,"activeCount":99},[],{"trials":1170,"activeCount":95,"soonestReadout":49},[1171],{"nctId":47,"briefTitle":48,"status":109,"phases":1172,"primaryCompletion":49,"completion":738,"start":1132,"enrollment":992,"conditions":1173,"interventions":1174},[88,89],[1134,1135],[50,1137,1138],{"trials":1176,"activeCount":99},[],{"trials":1178,"activeCount":99},[],{"trials":1180,"activeCount":99},[],{"intervention":1182,"totalTrials":95,"cells":1183},"freezedried autologous encapsulated fecal microbiota transplantation",{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1201,"PHASE4":1203,"NA":1205},{"trials":1185,"activeCount":99},[],{"trials":1187,"activeCount":99},[],{"trials":1189,"activeCount":95,"soonestReadout":1194},[1190],{"nctId":1191,"briefTitle":1192,"status":109,"phases":1193,"primaryCompletion":1194,"completion":1194,"start":1195,"enrollment":920,"conditions":1196,"interventions":1200},"NCT07083882","Faecal Autologous Capsule Transplantation for Type 1 Diabetes Mellitus",[89],"2029-09","2025-09",[1197,1198,1199],"Type 1 Diabetes Mellitis","Type 1 Diabetes (T1D)","Fecal Microbiota Therapy (FMT)",[1182],{"trials":1202,"activeCount":99},[],{"trials":1204,"activeCount":99},[],{"trials":1206,"activeCount":99},[],{"intervention":788,"totalTrials":95,"cells":1208},{"EARLY_PHASE1":1209,"PHASE1":1211,"PHASE2":1213,"PHASE3":1219,"PHASE4":1221,"NA":1223},{"trials":1210,"activeCount":99},[],{"trials":1212,"activeCount":99},[],{"trials":1214,"activeCount":95,"soonestReadout":84},[1215],{"nctId":780,"briefTitle":781,"status":109,"phases":1216,"primaryCompletion":84,"completion":783,"start":784,"enrollment":785,"conditions":1217,"interventions":1218},[89],[466,363],[326,327,788],{"trials":1220,"activeCount":99},[],{"trials":1222,"activeCount":99},[],{"trials":1224,"activeCount":99},[],{"intervention":40,"totalTrials":95,"cells":1226},{"EARLY_PHASE1":1227,"PHASE1":1229,"PHASE2":1231,"PHASE3":1237,"PHASE4":1239,"NA":1241},{"trials":1228,"activeCount":99},[],{"trials":1230,"activeCount":99},[],{"trials":1232,"activeCount":95,"soonestReadout":39},[1233],{"nctId":37,"briefTitle":38,"status":234,"phases":1234,"primaryCompletion":39,"completion":359,"start":360,"enrollment":361,"conditions":1235,"interventions":1236},[89],[363,364,365],[40,342,307],{"trials":1238,"activeCount":99},[],{"trials":1240,"activeCount":99},[],{"trials":1242,"activeCount":99},[],{"intervention":55,"totalTrials":1244,"cells":1245},3,{"EARLY_PHASE1":1246,"PHASE1":1248,"PHASE2":1250,"PHASE3":1273,"PHASE4":1275,"NA":1277},{"trials":1247,"activeCount":99},[],{"trials":1249,"activeCount":99},[],{"trials":1251,"activeCount":95,"soonestReadout":54},[1252,1265],{"nctId":1253,"briefTitle":1254,"status":333,"phases":1255,"primaryCompletion":1256,"completion":1257,"start":793,"enrollment":1258,"conditions":1259,"interventions":1261},"NCT01210911","Metformin Combined With Chemotherapy for Pancreatic Cancer",[89],"2014-02","2014-04",120,[1260,797],"Locally Advanced Pancreatic Cancer",[1262,1263,1264],"gemcitabine","erlotinib","metformin",{"nctId":52,"briefTitle":53,"status":109,"phases":1266,"primaryCompletion":54,"completion":1267,"start":1268,"enrollment":392,"conditions":1269,"interventions":1272},[89],"2029-10-01","2019-09-01",[1270,1271],"Superficial Bladder Cancer","Bladder Cancer",[55],{"trials":1274,"activeCount":99},[],{"trials":1276,"activeCount":99},[],{"trials":1278,"activeCount":99},[1279],{"nctId":1280,"briefTitle":1281,"status":333,"phases":1282,"primaryCompletion":1283,"completion":1283,"start":1284,"enrollment":1285,"conditions":1286,"interventions":1288},"NCT02783053","Metformin and Core Temperature in Obese and Lean Males",[92],"2016-06","2015-10",18,[1287],"Obesity",[55],{"intervention":1290,"totalTrials":95,"cells":1291},"Fluconazole 200mg tab",{"EARLY_PHASE1":1292,"PHASE1":1304,"PHASE2":1306,"PHASE3":1308,"PHASE4":1310,"NA":1312},{"trials":1293,"activeCount":95,"soonestReadout":1298},[1294],{"nctId":1295,"briefTitle":1296,"status":184,"phases":1297,"primaryCompletion":1298,"completion":1299,"start":964,"enrollment":992,"conditions":1300,"interventions":1303},"NCT07295314","Effect of Antifungals on the Intestinal Microbiome - a Randomized, Controlled, Proof-of-concept Trial",[87],"2027-10","2027-12",[898,1301,1302],"Healthy Adult Male","Antifungal Therapy",[1290],{"trials":1305,"activeCount":99},[],{"trials":1307,"activeCount":99},[],{"trials":1309,"activeCount":99},[],{"trials":1311,"activeCount":99},[],{"trials":1313,"activeCount":99},[],{"intervention":1315,"totalTrials":95,"cells":1316},"Statin",{"EARLY_PHASE1":1317,"PHASE1":1319,"PHASE2":1321,"PHASE3":1323,"PHASE4":1325,"NA":1327},{"trials":1318,"activeCount":99},[],{"trials":1320,"activeCount":99},[],{"trials":1322,"activeCount":99},[],{"trials":1324,"activeCount":99},[],{"trials":1326,"activeCount":99},[],{"trials":1328,"activeCount":95,"soonestReadout":1194},[1329],{"nctId":1330,"briefTitle":1331,"status":109,"phases":1332,"primaryCompletion":1194,"completion":1194,"start":1333,"enrollment":1334,"conditions":1335,"interventions":1338},"NCT06785740","Statins in Frail Older Patients with Ischemic Stroke or Transient Ischemic Attack - the Prospective Cohort Study",[],"2024-11-01",300,[1336,1337],"Ischemic Stroke","TIA",[1315],{"intervention":1340,"totalTrials":95,"cells":1341},"cefrtriaxone, gentamicin, cefuroxim, ciprofloxin or other antibiotics according to local guideline",{"EARLY_PHASE1":1342,"PHASE1":1344,"PHASE2":1346,"PHASE3":1348,"PHASE4":1350,"NA":1352},{"trials":1343,"activeCount":99},[],{"trials":1345,"activeCount":99},[],{"trials":1347,"activeCount":99},[],{"trials":1349,"activeCount":99},[],{"trials":1351,"activeCount":99},[],{"trials":1353,"activeCount":95,"soonestReadout":530},[1354],{"nctId":1355,"briefTitle":1356,"status":234,"phases":1357,"primaryCompletion":530,"completion":1358,"start":1359,"enrollment":1360,"conditions":1361,"interventions":1363},"NCT05750966","Short-course Antibiotics vs Standard Course Antibiotics in Patients With Cholangitis",[92],"2026-09-01","2023-07-19",440,[1362],"Cholangitis",[1340,1340],{"intervention":60,"totalTrials":95,"cells":1365},{"EARLY_PHASE1":1366,"PHASE1":1368,"PHASE2":1370,"PHASE3":1372,"PHASE4":1374,"NA":1376},{"trials":1367,"activeCount":99},[],{"trials":1369,"activeCount":99},[],{"trials":1371,"activeCount":99},[],{"trials":1373,"activeCount":99},[],{"trials":1375,"activeCount":99},[],{"trials":1377,"activeCount":95,"soonestReadout":59},[1378],{"nctId":57,"briefTitle":58,"status":109,"phases":1379,"primaryCompletion":59,"completion":1380,"start":360,"enrollment":1381,"conditions":1382,"interventions":1384},[],"2028-01",1300,[1383],"Cerebral Venous Thrombosis",[60],{"intervention":65,"totalTrials":95,"cells":1386},{"EARLY_PHASE1":1387,"PHASE1":1389,"PHASE2":1391,"PHASE3":1393,"PHASE4":1395,"NA":1397},{"trials":1388,"activeCount":99},[],{"trials":1390,"activeCount":99},[],{"trials":1392,"activeCount":99},[],{"trials":1394,"activeCount":99},[],{"trials":1396,"activeCount":99},[],{"trials":1398,"activeCount":95,"soonestReadout":64},[1399],{"nctId":62,"briefTitle":63,"status":234,"phases":1400,"primaryCompletion":64,"completion":262,"start":1401,"enrollment":95,"conditions":1402,"interventions":1404},[92],"2023-04-14",[1403],"Attention Deficit Disorder With Hyperactivity",[65,65],{"intervention":1406,"totalTrials":95,"cells":1407},"Optimal topical therapy",{"EARLY_PHASE1":1408,"PHASE1":1410,"PHASE2":1412,"PHASE3":1414,"PHASE4":1416,"NA":1418},{"trials":1409,"activeCount":99},[],{"trials":1411,"activeCount":99},[],{"trials":1413,"activeCount":99},[],{"trials":1415,"activeCount":99},[],{"trials":1417,"activeCount":99},[],{"trials":1419,"activeCount":95,"soonestReadout":1424},[1420],{"nctId":1421,"briefTitle":1422,"status":234,"phases":1423,"primaryCompletion":1424,"completion":1425,"start":1426,"enrollment":1427,"conditions":1428,"interventions":1429},"NCT05704205","The UPDATE Trial (Uvb Phototherapy in Dermatology for ATopic Eczema)",[92],"2026-01-16","2026-12","2023-02-22",316,[267,266],[1406],{"intervention":1431,"totalTrials":95,"cells":1432},"Hydrochlorothiazide",{"EARLY_PHASE1":1433,"PHASE1":1435,"PHASE2":1437,"PHASE3":1439,"PHASE4":1441,"NA":1443},{"trials":1434,"activeCount":99},[],{"trials":1436,"activeCount":99},[],{"trials":1438,"activeCount":99},[],{"trials":1440,"activeCount":99},[],{"trials":1442,"activeCount":99},[],{"trials":1444,"activeCount":95,"soonestReadout":1449},[1445],{"nctId":1446,"briefTitle":1447,"status":109,"phases":1448,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":1451,"conditions":1452,"interventions":1454},"NCT07020104","The Role of Skin Sodium Accumulation in Chronic Kidney Disease",[92],"2039-12-01","2025-01-07",60,[1453],"Chronic Kidney Diseases",[1431,1455,1456],"Spironolactone","Lercanidipine",{"intervention":1455,"totalTrials":95,"cells":1458},{"EARLY_PHASE1":1459,"PHASE1":1461,"PHASE2":1463,"PHASE3":1465,"PHASE4":1467,"NA":1469},{"trials":1460,"activeCount":99},[],{"trials":1462,"activeCount":99},[],{"trials":1464,"activeCount":99},[],{"trials":1466,"activeCount":99},[],{"trials":1468,"activeCount":99},[],{"trials":1470,"activeCount":95,"soonestReadout":1449},[1471],{"nctId":1446,"briefTitle":1447,"status":109,"phases":1472,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":1451,"conditions":1473,"interventions":1474},[92],[1453],[1431,1455,1456],{"intervention":1456,"totalTrials":95,"cells":1476},{"EARLY_PHASE1":1477,"PHASE1":1479,"PHASE2":1481,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1478,"activeCount":99},[],{"trials":1480,"activeCount":99},[],{"trials":1482,"activeCount":99},[],{"trials":1484,"activeCount":99},[],{"trials":1486,"activeCount":99},[],{"trials":1488,"activeCount":95,"soonestReadout":1449},[1489],{"nctId":1446,"briefTitle":1447,"status":109,"phases":1490,"primaryCompletion":1449,"completion":1449,"start":1450,"enrollment":1451,"conditions":1491,"interventions":1492},[92],[1453],[1431,1455,1456],{"intervention":75,"totalTrials":95,"cells":1494},{"EARLY_PHASE1":1495,"PHASE1":1497,"PHASE2":1499,"PHASE3":1501,"PHASE4":1503,"NA":1505},{"trials":1496,"activeCount":99},[],{"trials":1498,"activeCount":99},[],{"trials":1500,"activeCount":99},[],{"trials":1502,"activeCount":99},[],{"trials":1504,"activeCount":99},[],{"trials":1506,"activeCount":95,"soonestReadout":74},[1507],{"nctId":72,"briefTitle":73,"status":234,"phases":1508,"primaryCompletion":74,"completion":738,"start":1509,"enrollment":1510,"conditions":1511,"interventions":1513},[92],"2023-08-03",32,[1512],"Diabetes Mellitus, Type 2",[75],{"intervention":397,"totalTrials":95,"cells":1515},{"EARLY_PHASE1":1516,"PHASE1":1518,"PHASE2":1520,"PHASE3":1522,"PHASE4":1524,"NA":1526},{"trials":1517,"activeCount":99},[],{"trials":1519,"activeCount":99},[],{"trials":1521,"activeCount":99},[],{"trials":1523,"activeCount":99},[],{"trials":1525,"activeCount":99},[],{"trials":1527,"activeCount":95,"soonestReadout":290},[1528],{"nctId":387,"briefTitle":388,"status":109,"phases":1529,"primaryCompletion":290,"completion":390,"start":391,"enrollment":392,"conditions":1530,"interventions":1531},[92],[394,395],[397,342,307],{"intervention":1533,"totalTrials":367,"cells":1534},"mycophenol mofetil (MMF, Cellcept®) 500 mg BID",{"EARLY_PHASE1":1535,"PHASE1":1537,"PHASE2":1539,"PHASE3":1541,"PHASE4":1543,"NA":1560},{"trials":1536,"activeCount":99},[],{"trials":1538,"activeCount":99},[],{"trials":1540,"activeCount":99},[],{"trials":1542,"activeCount":99},[],{"trials":1544,"activeCount":99},[1545,1554],{"nctId":1546,"briefTitle":1547,"status":765,"phases":1548,"start":1549,"enrollment":1550,"conditions":1551,"interventions":1553},"NCT00120419","Mycophenolate Mofetil in Antiretroviral Naïve Patients 2 (MAN2 Study)",[91],"2005-04",90,[1552],"HIV Infection",[1533],{"nctId":1555,"briefTitle":1556,"status":765,"phases":1557,"start":1549,"enrollment":1550,"conditions":1558,"interventions":1559},"NCT00247494","Effects of Mycophenolate Mofetil (MMF) on Surrogate Markers for Cardiovascular Disease in HIV-1 Infected Patients",[91],[1552,642],[1533],{"trials":1561,"activeCount":99},[],{"intervention":1563,"totalTrials":95,"cells":1564},"Infliximab",{"EARLY_PHASE1":1565,"PHASE1":1567,"PHASE2":1569,"PHASE3":1571,"PHASE4":1573,"NA":1585},{"trials":1566,"activeCount":99},[],{"trials":1568,"activeCount":99},[],{"trials":1570,"activeCount":99},[],{"trials":1572,"activeCount":99},[],{"trials":1574,"activeCount":99},[1575],{"nctId":1576,"briefTitle":1577,"status":1578,"phases":1579,"primaryCompletion":1580,"completion":1580,"start":1581,"enrollment":992,"conditions":1582,"interventions":1584},"NCT03937609","TITRATE (inducTIon for acuTe ulceRATivE Colitis)","TERMINATED",[91],"2024-12-15","2019-09-04",[1583],"Colitis, Ulcerative",[1563],{"trials":1586,"activeCount":99},[],{"intervention":1588,"totalTrials":95,"cells":1589},"Fluticasone proprionate 0.05% cream",{"EARLY_PHASE1":1590,"PHASE1":1592,"PHASE2":1594,"PHASE3":1596,"PHASE4":1598,"NA":1610},{"trials":1591,"activeCount":99},[],{"trials":1593,"activeCount":99},[],{"trials":1595,"activeCount":99},[],{"trials":1597,"activeCount":99},[],{"trials":1599,"activeCount":99},[1600],{"nctId":1601,"briefTitle":1602,"status":765,"phases":1603,"primaryCompletion":794,"start":1604,"enrollment":992,"conditions":1605,"interventions":1609},"NCT01246921","Effect of Fluticasone Proprionate 0.05% on Narrow Band UV-B in Active Vitiligo",[91],"2009-09",[1606,1607,1608],"Patients With Active Non-segmental Vitiligo.","Evaluation of the Efficacy of UVB and Fluticason Proprionate 0.05%","Cream Compared to NB-UVB Alone in Patients With Non-segmental Vitiligo",[1588],{"trials":1611,"activeCount":99},[],{"intervention":1613,"totalTrials":95,"cells":1614},"PRECISION dosing Infliximab",{"EARLY_PHASE1":1615,"PHASE1":1617,"PHASE2":1619,"PHASE3":1621,"PHASE4":1623,"NA":1635},{"trials":1616,"activeCount":99},[],{"trials":1618,"activeCount":99},[],{"trials":1620,"activeCount":99},[],{"trials":1622,"activeCount":99},[],{"trials":1624,"activeCount":99},[1625],{"nctId":1626,"briefTitle":1627,"status":333,"phases":1628,"primaryCompletion":1629,"completion":1629,"start":1630,"enrollment":1631,"conditions":1632,"interventions":1634},"NCT02453776","Precision Dosing of Infliximab Versus Conventional Dosing of Infliximab",[91],"2018-12","2015-05",80,[1633],"Inflammatory Bowel Disease",[1613],{"trials":1636,"activeCount":99},[],{"intervention":1638,"totalTrials":95,"cells":1639},"Bupivacaine",{"EARLY_PHASE1":1640,"PHASE1":1642,"PHASE2":1644,"PHASE3":1646,"PHASE4":1648,"NA":1667},{"trials":1641,"activeCount":99},[],{"trials":1643,"activeCount":99},[],{"trials":1645,"activeCount":99},[],{"trials":1647,"activeCount":99},[],{"trials":1649,"activeCount":99},[1650],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1653,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1656,"interventions":1658},"NCT02689024","Delirium in Elderly Patients With Trauma of the Hip",[91],"2016-05",239,[1657,29],"Hip Fractures",[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],"Acetaminophen","Diclofenac","Ibuprofen","Naproxen","Dipyrone","Morphine","Levobupivacaine","Ropivacaine",{"trials":1668,"activeCount":99},[],{"intervention":1659,"totalTrials":95,"cells":1670},{"EARLY_PHASE1":1671,"PHASE1":1673,"PHASE2":1675,"PHASE3":1677,"PHASE4":1679,"NA":1685},{"trials":1672,"activeCount":99},[],{"trials":1674,"activeCount":99},[],{"trials":1676,"activeCount":99},[],{"trials":1678,"activeCount":99},[],{"trials":1680,"activeCount":99},[1681],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1682,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1683,"interventions":1684},[91],[1657,29],[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],{"trials":1686,"activeCount":99},[],{"intervention":1660,"totalTrials":95,"cells":1688},{"EARLY_PHASE1":1689,"PHASE1":1691,"PHASE2":1693,"PHASE3":1695,"PHASE4":1697,"NA":1703},{"trials":1690,"activeCount":99},[],{"trials":1692,"activeCount":99},[],{"trials":1694,"activeCount":99},[],{"trials":1696,"activeCount":99},[],{"trials":1698,"activeCount":99},[1699],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1700,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1701,"interventions":1702},[91],[1657,29],[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],{"trials":1704,"activeCount":99},[],{"intervention":1661,"totalTrials":95,"cells":1706},{"EARLY_PHASE1":1707,"PHASE1":1709,"PHASE2":1711,"PHASE3":1713,"PHASE4":1715,"NA":1721},{"trials":1708,"activeCount":99},[],{"trials":1710,"activeCount":99},[],{"trials":1712,"activeCount":99},[],{"trials":1714,"activeCount":99},[],{"trials":1716,"activeCount":99},[1717],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1718,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1719,"interventions":1720},[91],[1657,29],[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],{"trials":1722,"activeCount":99},[],{"intervention":1662,"totalTrials":95,"cells":1724},{"EARLY_PHASE1":1725,"PHASE1":1727,"PHASE2":1729,"PHASE3":1731,"PHASE4":1733,"NA":1739},{"trials":1726,"activeCount":99},[],{"trials":1728,"activeCount":99},[],{"trials":1730,"activeCount":99},[],{"trials":1732,"activeCount":99},[],{"trials":1734,"activeCount":99},[1735],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1736,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1737,"interventions":1738},[91],[1657,29],[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],{"trials":1740,"activeCount":99},[],{"intervention":1663,"totalTrials":95,"cells":1742},{"EARLY_PHASE1":1743,"PHASE1":1745,"PHASE2":1747,"PHASE3":1749,"PHASE4":1751,"NA":1757},{"trials":1744,"activeCount":99},[],{"trials":1746,"activeCount":99},[],{"trials":1748,"activeCount":99},[],{"trials":1750,"activeCount":99},[],{"trials":1752,"activeCount":99},[1753],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1754,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1755,"interventions":1756},[91],[1657,29],[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],{"trials":1758,"activeCount":99},[],{"intervention":696,"totalTrials":95,"cells":1760},{"EARLY_PHASE1":1761,"PHASE1":1763,"PHASE2":1765,"PHASE3":1767,"PHASE4":1769,"NA":1775},{"trials":1762,"activeCount":99},[],{"trials":1764,"activeCount":99},[],{"trials":1766,"activeCount":99},[],{"trials":1768,"activeCount":99},[],{"trials":1770,"activeCount":99},[1771],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1772,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1773,"interventions":1774},[91],[1657,29],[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],{"trials":1776,"activeCount":99},[],{"intervention":1664,"totalTrials":95,"cells":1778},{"EARLY_PHASE1":1779,"PHASE1":1781,"PHASE2":1783,"PHASE3":1785,"PHASE4":1787,"NA":1793},{"trials":1780,"activeCount":99},[],{"trials":1782,"activeCount":99},[],{"trials":1784,"activeCount":99},[],{"trials":1786,"activeCount":99},[],{"trials":1788,"activeCount":99},[1789],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1790,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1791,"interventions":1792},[91],[1657,29],[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],{"trials":1794,"activeCount":99},[],{"intervention":1665,"totalTrials":95,"cells":1796},{"EARLY_PHASE1":1797,"PHASE1":1799,"PHASE2":1801,"PHASE3":1803,"PHASE4":1805,"NA":1811},{"trials":1798,"activeCount":99},[],{"trials":1800,"activeCount":99},[],{"trials":1802,"activeCount":99},[],{"trials":1804,"activeCount":99},[],{"trials":1806,"activeCount":99},[1807],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1808,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1809,"interventions":1810},[91],[1657,29],[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],{"trials":1812,"activeCount":99},[],{"intervention":1666,"totalTrials":95,"cells":1814},{"EARLY_PHASE1":1815,"PHASE1":1817,"PHASE2":1819,"PHASE3":1821,"PHASE4":1823,"NA":1829},{"trials":1816,"activeCount":99},[],{"trials":1818,"activeCount":99},[],{"trials":1820,"activeCount":99},[],{"trials":1822,"activeCount":99},[],{"trials":1824,"activeCount":99},[1825],{"nctId":1651,"briefTitle":1652,"status":1578,"phases":1826,"primaryCompletion":1359,"completion":1359,"start":1654,"enrollment":1655,"conditions":1827,"interventions":1828},[91],[1657,29],[1638,1659,1660,1661,1662,1663,696,1664,1665,1666],{"trials":1830,"activeCount":99},[],{"intervention":1832,"totalTrials":95,"cells":1833},"Standard Continuous Highly Active Antiretroviral Therapy",{"EARLY_PHASE1":1834,"PHASE1":1836,"PHASE2":1838,"PHASE3":1840,"PHASE4":1842,"NA":1854},{"trials":1835,"activeCount":99},[],{"trials":1837,"activeCount":99},[],{"trials":1839,"activeCount":99},[],{"trials":1841,"activeCount":99},[],{"trials":1843,"activeCount":99},[1844],{"nctId":1845,"briefTitle":1846,"status":1578,"phases":1847,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":1244,"conditions":1850,"interventions":1852},"NCT00128908","Sequential HIV Therapy in Treatment Resistant HIV-1 Infected Patients",[91],"2007-01","2005-09",[1851],"HIV Infections",[1832,1853],"Rapidly Cycled HAART",{"trials":1855,"activeCount":99},[],{"intervention":1853,"totalTrials":95,"cells":1857},{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1862,"PHASE3":1864,"PHASE4":1866,"NA":1872},{"trials":1859,"activeCount":99},[],{"trials":1861,"activeCount":99},[],{"trials":1863,"activeCount":99},[],{"trials":1865,"activeCount":99},[],{"trials":1867,"activeCount":99},[1868],{"nctId":1845,"briefTitle":1846,"status":1578,"phases":1869,"primaryCompletion":1848,"completion":1848,"start":1849,"enrollment":1244,"conditions":1870,"interventions":1871},[91],[1851],[1832,1853],{"trials":1873,"activeCount":99},[],{"intervention":1875,"totalTrials":95,"cells":1876},"No aspirin",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1883,"PHASE4":1885,"NA":1898},{"trials":1878,"activeCount":99},[],{"trials":1880,"activeCount":99},[],{"trials":1882,"activeCount":99},[],{"trials":1884,"activeCount":99},[],{"trials":1886,"activeCount":99},[1887],{"nctId":1888,"briefTitle":1889,"status":765,"phases":1890,"primaryCompletion":1891,"completion":1891,"start":1892,"enrollment":1893,"conditions":1894,"interventions":1896},"NCT05125276","Less Bleeding by Omitting Aspirin in Non-ST-segment Elevation Acute Coronary Syndrome Patients",[91],"2025-07","2022-05-13",3090,[1895],"Non ST Segment Elevation Acute Coronary Syndrome",[1875,1897],"Aspirin",{"trials":1899,"activeCount":99},[],{"intervention":1897,"totalTrials":95,"cells":1901},{"EARLY_PHASE1":1902,"PHASE1":1904,"PHASE2":1906,"PHASE3":1908,"PHASE4":1910,"NA":1916},{"trials":1903,"activeCount":99},[],{"trials":1905,"activeCount":99},[],{"trials":1907,"activeCount":99},[],{"trials":1909,"activeCount":99},[],{"trials":1911,"activeCount":99},[1912],{"nctId":1888,"briefTitle":1889,"status":765,"phases":1913,"primaryCompletion":1891,"completion":1891,"start":1892,"enrollment":1893,"conditions":1914,"interventions":1915},[91],[1895],[1875,1897],{"trials":1917,"activeCount":99},[],{"intervention":1919,"totalTrials":95,"cells":1920},"Atosiban",{"EARLY_PHASE1":1921,"PHASE1":1923,"PHASE2":1925,"PHASE3":1927,"PHASE4":1929,"NA":1941},{"trials":1922,"activeCount":99},[],{"trials":1924,"activeCount":99},[],{"trials":1926,"activeCount":99},[],{"trials":1928,"activeCount":99},[],{"trials":1930,"activeCount":99},[1931],{"nctId":1932,"briefTitle":1933,"status":333,"phases":1934,"primaryCompletion":1935,"completion":1935,"start":1936,"enrollment":1937,"conditions":1938,"interventions":1940},"NCT05693688","Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth",[91],"2024-02-29","2017-12-01",760,[1939],"Preterm Birth",[1919],{"trials":1942,"activeCount":99},[],{"intervention":1944,"totalTrials":95,"cells":1945},"Citalopram 20mg",{"EARLY_PHASE1":1946,"PHASE1":1948,"PHASE2":1950,"PHASE3":1952,"PHASE4":1954,"NA":1965},{"trials":1947,"activeCount":99},[],{"trials":1949,"activeCount":99},[],{"trials":1951,"activeCount":99},[],{"trials":1953,"activeCount":99},[],{"trials":1955,"activeCount":99},[1956],{"nctId":1957,"briefTitle":1958,"status":1578,"phases":1959,"primaryCompletion":1960,"completion":1960,"start":1961,"enrollment":95,"conditions":1962,"interventions":1964},"NCT05735756","Effect of Citalopram on Chest Pain in Patients With Functional Chest Pain",[91],"2022-04-22","2022-01-17",[1963],"Functional Chest Pain",[1944],{"trials":1966,"activeCount":99},[],{"intervention":1968,"totalTrials":95,"cells":1969},"Amoxicillin-clavulanate",{"EARLY_PHASE1":1970,"PHASE1":1972,"PHASE2":1974,"PHASE3":1976,"PHASE4":1978,"NA":1991},{"trials":1971,"activeCount":99},[],{"trials":1973,"activeCount":99},[],{"trials":1975,"activeCount":99},[],{"trials":1977,"activeCount":99},[],{"trials":1979,"activeCount":99},[1980],{"nctId":1981,"briefTitle":1982,"status":765,"phases":1983,"primaryCompletion":1984,"completion":1985,"start":1986,"enrollment":1987,"conditions":1988,"interventions":1990},"NCT01111253","Diverticulitis: Antibiotics or Close Observation?",[91],"2013-04","2014-10","2010-05",533,[1989],"Diverticulitis",[1968],{"trials":1992,"activeCount":99},[],{"intervention":1994,"totalTrials":95,"cells":1995},"Flucloxacillin",{"EARLY_PHASE1":1996,"PHASE1":1998,"PHASE2":2000,"PHASE3":2002,"PHASE4":2004,"NA":2018},{"trials":1997,"activeCount":99},[],{"trials":1999,"activeCount":99},[],{"trials":2001,"activeCount":99},[],{"trials":2003,"activeCount":99},[],{"trials":2005,"activeCount":99},[2006],{"nctId":2007,"briefTitle":2008,"status":1578,"phases":2009,"primaryCompletion":2010,"completion":2011,"start":2012,"enrollment":2013,"conditions":2014,"interventions":2017},"NCT02032654","Duration of ANtibiotic Therapy for CEllulitis",[91],"2017-07-24","2017-09-25","2014-08-26",151,[2015,2016],"Cellulitis","Erysipelas",[1994],{"trials":2019,"activeCount":99},[],{"intervention":2021,"totalTrials":95,"cells":2022},"Naltrexone",{"EARLY_PHASE1":2023,"PHASE1":2025,"PHASE2":2027,"PHASE3":2029,"PHASE4":2031,"NA":2042},{"trials":2024,"activeCount":99},[],{"trials":2026,"activeCount":99},[],{"trials":2028,"activeCount":99},[],{"trials":2030,"activeCount":99},[],{"trials":2032,"activeCount":99},[2033],{"nctId":2034,"briefTitle":2035,"status":333,"phases":2036,"primaryCompletion":1985,"completion":1985,"start":2037,"enrollment":113,"conditions":2038,"interventions":2041},"NCT01471145","Depot Naltrexone Mechanism of Action in Heroin Dependent Patients Using fMRI and SPECT",[91],"2013-01",[2039,2040],"Opioid-Related Disorders","Heroin Dependence",[2021],{"trials":2043,"activeCount":99},[],{"intervention":2045,"totalTrials":95,"cells":2046},"Cephalozin",{"EARLY_PHASE1":2047,"PHASE1":2049,"PHASE2":2051,"PHASE3":2053,"PHASE4":2055,"NA":2067},{"trials":2048,"activeCount":99},[],{"trials":2050,"activeCount":99},[],{"trials":2052,"activeCount":99},[],{"trials":2054,"activeCount":99},[],{"trials":2056,"activeCount":99},[2057],{"nctId":2058,"briefTitle":2059,"status":333,"phases":2060,"primaryCompletion":2061,"completion":2061,"start":2062,"enrollment":2063,"conditions":2064,"interventions":2066},"NCT02225821","Wound Infections Following Implant Removal",[91],"2016-11","2014-11",500,[2065],"Surgical Wound Infection",[2045],{"trials":2068,"activeCount":99},[],{"intervention":2070,"totalTrials":95,"cells":2071},"Semaglutide, 2.0 mg\u002FmL",{"EARLY_PHASE1":2072,"PHASE1":2074,"PHASE2":2076,"PHASE3":2078,"PHASE4":2080,"NA":2092},{"trials":2073,"activeCount":99},[],{"trials":2075,"activeCount":99},[],{"trials":2077,"activeCount":99},[],{"trials":2079,"activeCount":99},[],{"trials":2081,"activeCount":99},[2082],{"nctId":2083,"briefTitle":2084,"status":765,"phases":2085,"primaryCompletion":2086,"completion":2087,"start":2088,"enrollment":967,"conditions":2089,"interventions":2091},"NCT05597202","Does the Hematopoietic Stem Cell Govern Residual Inflammatory Cardiovascular Risk in Type 2 Diabetes",[91],"2024-03","2024-04","2023-01-01",[2090],"Type 2 Diabetes",[2070],{"trials":2093,"activeCount":99},[],{"intervention":2095,"totalTrials":95,"cells":2096},"Rocuronium",{"EARLY_PHASE1":2097,"PHASE1":2099,"PHASE2":2101,"PHASE3":2103,"PHASE4":2105,"NA":2117},{"trials":2098,"activeCount":99},[],{"trials":2100,"activeCount":99},[],{"trials":2102,"activeCount":99},[],{"trials":2104,"activeCount":99},[],{"trials":2106,"activeCount":99},[2107],{"nctId":2108,"briefTitle":2109,"status":333,"phases":2110,"primaryCompletion":2111,"completion":2111,"start":2112,"enrollment":2113,"conditions":2114,"interventions":2116},"NCT02320734","Deep Neuromuscular Relaxation in Patients for Thoraco-laparoscopic Esophagectomy",[91],"2016-09","2015-02",66,[2115,18,24],"Neuromuscular Block",[2095],{"trials":2118,"activeCount":99},[],{"intervention":2120,"totalTrials":95,"cells":2121},"Low dose nadroparin",{"EARLY_PHASE1":2122,"PHASE1":2124,"PHASE2":2126,"PHASE3":2128,"PHASE4":2130,"NA":2150},{"trials":2123,"activeCount":99},[],{"trials":2125,"activeCount":99},[],{"trials":2127,"activeCount":99},[],{"trials":2129,"activeCount":99},[],{"trials":2131,"activeCount":99},[2132],{"nctId":2133,"briefTitle":2134,"status":333,"phases":2135,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2139,"interventions":2142},"NCT01828697","Comparison of Low and Intermediate Dose Low-molecular-weight Heparin to Prevent Recurrent Venous Thromboembolism in Pregnancy",[91],"2021-10-31","2013-04-24",1110,[2140,2141],"Deep Venous Thrombosis","Pulmonary Embolism",[2120,2143,2144,2145,2146,2147,2148,2149],"Intermediate dose nadroparin","Low dose enoxaparin","Intermediate dose enoxaparin","Low dose dalteparin","Intermediate dose dalteparin","Fixed low dose tinzaparin","Intermediate dose tinzaparin",{"trials":2151,"activeCount":99},[],{"intervention":2143,"totalTrials":95,"cells":2153},{"EARLY_PHASE1":2154,"PHASE1":2156,"PHASE2":2158,"PHASE3":2160,"PHASE4":2162,"NA":2168},{"trials":2155,"activeCount":99},[],{"trials":2157,"activeCount":99},[],{"trials":2159,"activeCount":99},[],{"trials":2161,"activeCount":99},[],{"trials":2163,"activeCount":99},[2164],{"nctId":2133,"briefTitle":2134,"status":333,"phases":2165,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2166,"interventions":2167},[91],[2140,2141],[2120,2143,2144,2145,2146,2147,2148,2149],{"trials":2169,"activeCount":99},[],{"intervention":2144,"totalTrials":95,"cells":2171},{"EARLY_PHASE1":2172,"PHASE1":2174,"PHASE2":2176,"PHASE3":2178,"PHASE4":2180,"NA":2186},{"trials":2173,"activeCount":99},[],{"trials":2175,"activeCount":99},[],{"trials":2177,"activeCount":99},[],{"trials":2179,"activeCount":99},[],{"trials":2181,"activeCount":99},[2182],{"nctId":2133,"briefTitle":2134,"status":333,"phases":2183,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2184,"interventions":2185},[91],[2140,2141],[2120,2143,2144,2145,2146,2147,2148,2149],{"trials":2187,"activeCount":99},[],{"intervention":2145,"totalTrials":95,"cells":2189},{"EARLY_PHASE1":2190,"PHASE1":2192,"PHASE2":2194,"PHASE3":2196,"PHASE4":2198,"NA":2204},{"trials":2191,"activeCount":99},[],{"trials":2193,"activeCount":99},[],{"trials":2195,"activeCount":99},[],{"trials":2197,"activeCount":99},[],{"trials":2199,"activeCount":99},[2200],{"nctId":2133,"briefTitle":2134,"status":333,"phases":2201,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2202,"interventions":2203},[91],[2140,2141],[2120,2143,2144,2145,2146,2147,2148,2149],{"trials":2205,"activeCount":99},[],{"intervention":2146,"totalTrials":95,"cells":2207},{"EARLY_PHASE1":2208,"PHASE1":2210,"PHASE2":2212,"PHASE3":2214,"PHASE4":2216,"NA":2222},{"trials":2209,"activeCount":99},[],{"trials":2211,"activeCount":99},[],{"trials":2213,"activeCount":99},[],{"trials":2215,"activeCount":99},[],{"trials":2217,"activeCount":99},[2218],{"nctId":2133,"briefTitle":2134,"status":333,"phases":2219,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2220,"interventions":2221},[91],[2140,2141],[2120,2143,2144,2145,2146,2147,2148,2149],{"trials":2223,"activeCount":99},[],{"intervention":2147,"totalTrials":95,"cells":2225},{"EARLY_PHASE1":2226,"PHASE1":2228,"PHASE2":2230,"PHASE3":2232,"PHASE4":2234,"NA":2240},{"trials":2227,"activeCount":99},[],{"trials":2229,"activeCount":99},[],{"trials":2231,"activeCount":99},[],{"trials":2233,"activeCount":99},[],{"trials":2235,"activeCount":99},[2236],{"nctId":2133,"briefTitle":2134,"status":333,"phases":2237,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2238,"interventions":2239},[91],[2140,2141],[2120,2143,2144,2145,2146,2147,2148,2149],{"trials":2241,"activeCount":99},[],{"intervention":2148,"totalTrials":95,"cells":2243},{"EARLY_PHASE1":2244,"PHASE1":2246,"PHASE2":2248,"PHASE3":2250,"PHASE4":2252,"NA":2258},{"trials":2245,"activeCount":99},[],{"trials":2247,"activeCount":99},[],{"trials":2249,"activeCount":99},[],{"trials":2251,"activeCount":99},[],{"trials":2253,"activeCount":99},[2254],{"nctId":2133,"briefTitle":2134,"status":333,"phases":2255,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2256,"interventions":2257},[91],[2140,2141],[2120,2143,2144,2145,2146,2147,2148,2149],{"trials":2259,"activeCount":99},[],{"intervention":2149,"totalTrials":95,"cells":2261},{"EARLY_PHASE1":2262,"PHASE1":2264,"PHASE2":2266,"PHASE3":2268,"PHASE4":2270,"NA":2276},{"trials":2263,"activeCount":99},[],{"trials":2265,"activeCount":99},[],{"trials":2267,"activeCount":99},[],{"trials":2269,"activeCount":99},[],{"trials":2271,"activeCount":99},[2272],{"nctId":2133,"briefTitle":2134,"status":333,"phases":2273,"primaryCompletion":2136,"completion":2136,"start":2137,"enrollment":2138,"conditions":2274,"interventions":2275},[91],[2140,2141],[2120,2143,2144,2145,2146,2147,2148,2149],{"trials":2277,"activeCount":99},[],{"intervention":2279,"totalTrials":95,"cells":2280},"Vitamin D",{"EARLY_PHASE1":2281,"PHASE1":2283,"PHASE2":2285,"PHASE3":2287,"PHASE4":2289,"NA":2301},{"trials":2282,"activeCount":99},[],{"trials":2284,"activeCount":99},[],{"trials":2286,"activeCount":99},[],{"trials":2288,"activeCount":99},[],{"trials":2290,"activeCount":99},[2291],{"nctId":2292,"briefTitle":2293,"status":333,"phases":2294,"primaryCompletion":2295,"completion":2295,"start":2296,"enrollment":2297,"conditions":2298,"interventions":2300},"NCT02010762","The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease",[91],"2017-12","2013-02",142,[2299],"Crohn's Disease",[2279],{"trials":2302,"activeCount":99},[],{"intervention":2304,"totalTrials":95,"cells":2305},"Continuous intrajejunal infusion of levodopa-carbidopa",{"EARLY_PHASE1":2306,"PHASE1":2308,"PHASE2":2310,"PHASE3":2312,"PHASE4":2314,"NA":2327},{"trials":2307,"activeCount":99},[],{"trials":2309,"activeCount":99},[],{"trials":2311,"activeCount":99},[],{"trials":2313,"activeCount":99},[],{"trials":2315,"activeCount":99},[2316],{"nctId":2317,"briefTitle":2318,"status":333,"phases":2319,"primaryCompletion":2320,"completion":2321,"start":2322,"enrollment":2323,"conditions":2324,"interventions":2326},"NCT02480803","INfusion VErsus STimulation in Parkinson's Disease",[91],"2021-12-07","2024-01-26","2014-12-19",51,[2325],"Parkinson's Disease",[2304],{"trials":2328,"activeCount":99},[],{"intervention":2330,"totalTrials":95,"cells":2331},"Estradiol patch",{"EARLY_PHASE1":2332,"PHASE1":2334,"PHASE2":2336,"PHASE3":2338,"PHASE4":2340,"NA":2353},{"trials":2333,"activeCount":99},[],{"trials":2335,"activeCount":99},[],{"trials":2337,"activeCount":99},[],{"trials":2339,"activeCount":99},[],{"trials":2341,"activeCount":99},[2342],{"nctId":2343,"briefTitle":2344,"status":333,"phases":2345,"primaryCompletion":2346,"completion":2347,"start":1359,"enrollment":888,"conditions":2348,"interventions":2351},"NCT05903820","Rhythmic Estradiol and Bone Health",[91],"2024-10-21","2024-10-28",[2349,2350],"Osteoporosis Risk","Menopause",[2330,2352],"Progesterone",{"trials":2354,"activeCount":99},[],{"intervention":2352,"totalTrials":95,"cells":2356},{"EARLY_PHASE1":2357,"PHASE1":2359,"PHASE2":2361,"PHASE3":2363,"PHASE4":2365,"NA":2371},{"trials":2358,"activeCount":99},[],{"trials":2360,"activeCount":99},[],{"trials":2362,"activeCount":99},[],{"trials":2364,"activeCount":99},[],{"trials":2366,"activeCount":99},[2367],{"nctId":2343,"briefTitle":2344,"status":333,"phases":2368,"primaryCompletion":2346,"completion":2347,"start":1359,"enrollment":888,"conditions":2369,"interventions":2370},[91],[2349,2350],[2330,2352],{"trials":2372,"activeCount":99},[],{"intervention":2374,"totalTrials":95,"cells":2375},"Empagliflozin 10 MG",{"EARLY_PHASE1":2376,"PHASE1":2378,"PHASE2":2380,"PHASE3":2382,"PHASE4":2384,"NA":2395},{"trials":2377,"activeCount":99},[],{"trials":2379,"activeCount":99},[],{"trials":2381,"activeCount":99},[],{"trials":2383,"activeCount":99},[],{"trials":2385,"activeCount":99},[2386],{"nctId":2387,"briefTitle":2388,"status":333,"phases":2389,"primaryCompletion":2390,"completion":2390,"start":2391,"enrollment":1451,"conditions":2392,"interventions":2394},"NCT06825156","Metabolic and Renal Outcomes in Cardiac Surgery Patients Receiving SGLT2 Inhibitors",[91],"2023-05-26","2022-03-03",[2393],"Acute Kidney Injury",[2374],{"trials":2396,"activeCount":99},[],{"intervention":2398,"totalTrials":95,"cells":2399},"Ferrous fumarate",{"EARLY_PHASE1":2400,"PHASE1":2402,"PHASE2":2404,"PHASE3":2406,"PHASE4":2408,"NA":2422},{"trials":2401,"activeCount":99},[],{"trials":2403,"activeCount":99},[],{"trials":2405,"activeCount":99},[],{"trials":2407,"activeCount":99},[],{"trials":2409,"activeCount":99},[2410],{"nctId":2411,"briefTitle":2412,"status":765,"phases":2413,"primaryCompletion":2414,"completion":2415,"start":2062,"enrollment":2416,"conditions":2417,"interventions":2420},"NCT02243735","Trial Comparing Ferric(III)Carboxymaltose Infusion With Oral Iron Suppletion as Treatment of Anaemia",[91],"2019-11","2019-12",198,[2418,2419,24],"Anemia","Colorectal Carcinoma",[2398,2421],"ferric(III)carboxymaltose",{"trials":2423,"activeCount":99},[],{"intervention":2421,"totalTrials":95,"cells":2425},{"EARLY_PHASE1":2426,"PHASE1":2428,"PHASE2":2430,"PHASE3":2432,"PHASE4":2434,"NA":2440},{"trials":2427,"activeCount":99},[],{"trials":2429,"activeCount":99},[],{"trials":2431,"activeCount":99},[],{"trials":2433,"activeCount":99},[],{"trials":2435,"activeCount":99},[2436],{"nctId":2411,"briefTitle":2412,"status":765,"phases":2437,"primaryCompletion":2414,"completion":2415,"start":2062,"enrollment":2416,"conditions":2438,"interventions":2439},[91],[2418,2419,24],[2398,2421],{"trials":2441,"activeCount":99},[],{"intervention":2443,"totalTrials":95,"cells":2444},"anti-tumour necrosis factor α antibodies",{"EARLY_PHASE1":2445,"PHASE1":2447,"PHASE2":2449,"PHASE3":2451,"PHASE4":2465,"NA":2467},{"trials":2446,"activeCount":99},[],{"trials":2448,"activeCount":99},[],{"trials":2450,"activeCount":99},[],{"trials":2452,"activeCount":99},[2453],{"nctId":2454,"briefTitle":2455,"status":333,"phases":2456,"primaryCompletion":2457,"completion":2458,"start":2459,"enrollment":2460,"conditions":2461,"interventions":2464},"NCT06441526","Surgical Closure vs Anti-TNF in the Treatment of Perianal Fistulas in Crohn's Disease (PISA-II): a Comprehensive Cohort Design",[90],"2019-12-07","2021-06-07","2013-09-14",94,[2462,2463],"Perianal Fistula","Crohn Disease",[2443],{"trials":2466,"activeCount":99},[],{"trials":2468,"activeCount":99},[],{"intervention":2470,"totalTrials":95,"cells":2471},"Tranexamic Acid",{"EARLY_PHASE1":2472,"PHASE1":2474,"PHASE2":2476,"PHASE3":2478,"PHASE4":2491,"NA":2493},{"trials":2473,"activeCount":99},[],{"trials":2475,"activeCount":99},[],{"trials":2477,"activeCount":99},[],{"trials":2479,"activeCount":99},[2480],{"nctId":2481,"briefTitle":2482,"status":333,"phases":2483,"primaryCompletion":2484,"completion":2485,"start":2486,"enrollment":2487,"conditions":2488,"interventions":2490},"NCT02684812","Ultra-early Tranexamic Acid After Subarachnoid Hemorrhage.",[89,90],"2019-07-29","2020-11-01","2012-07-16",955,[2489],"Subarachnoid Hemorrhage",[2470],{"trials":2492,"activeCount":99},[],{"trials":2494,"activeCount":99},[],{"intervention":2496,"totalTrials":95,"cells":2497},"Sildenafil",{"EARLY_PHASE1":2498,"PHASE1":2500,"PHASE2":2502,"PHASE3":2504,"PHASE4":2515,"NA":2517},{"trials":2499,"activeCount":99},[],{"trials":2501,"activeCount":99},[],{"trials":2503,"activeCount":99},[],{"trials":2505,"activeCount":99},[2506],{"nctId":2507,"briefTitle":2508,"status":1578,"phases":2509,"primaryCompletion":2510,"completion":2510,"start":2511,"enrollment":264,"conditions":2512,"interventions":2514},"NCT02277132","The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)",[89,90],"2018-07-19","2015-01",[2513],"Fetal Growth Restriction",[2496],{"trials":2516,"activeCount":99},[],{"trials":2518,"activeCount":99},[],{"intervention":2520,"totalTrials":95,"cells":2521},"Bevacizumab",{"EARLY_PHASE1":2522,"PHASE1":2524,"PHASE2":2526,"PHASE3":2528,"PHASE4":2540,"NA":2542},{"trials":2523,"activeCount":99},[],{"trials":2525,"activeCount":99},[],{"trials":2527,"activeCount":99},[],{"trials":2529,"activeCount":99},[2530],{"nctId":2531,"briefTitle":2532,"status":765,"phases":2533,"primaryCompletion":1283,"start":2534,"enrollment":2535,"conditions":2536,"interventions":2538},"NCT01635803","Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)",[89,90],"2012-06",296,[2537],"Retinal Vein Occlusion",[2520,2539],"Ranibizumab",{"trials":2541,"activeCount":99},[],{"trials":2543,"activeCount":99},[],{"intervention":2539,"totalTrials":95,"cells":2545},{"EARLY_PHASE1":2546,"PHASE1":2548,"PHASE2":2550,"PHASE3":2552,"PHASE4":2558,"NA":2560},{"trials":2547,"activeCount":99},[],{"trials":2549,"activeCount":99},[],{"trials":2551,"activeCount":99},[],{"trials":2553,"activeCount":99},[2554],{"nctId":2531,"briefTitle":2532,"status":765,"phases":2555,"primaryCompletion":1283,"start":2534,"enrollment":2535,"conditions":2556,"interventions":2557},[89,90],[2537],[2520,2539],{"trials":2559,"activeCount":99},[],{"trials":2561,"activeCount":99},[],{"intervention":2563,"totalTrials":95,"cells":2564},"Propranolol",{"EARLY_PHASE1":2565,"PHASE1":2567,"PHASE2":2569,"PHASE3":2571,"PHASE4":2580,"NA":2582},{"trials":2566,"activeCount":99},[],{"trials":2568,"activeCount":99},[],{"trials":2570,"activeCount":99},[],{"trials":2572,"activeCount":99},[2573],{"nctId":2574,"briefTitle":2575,"status":333,"phases":2576,"primaryCompletion":1629,"completion":1629,"start":2062,"enrollment":9,"conditions":2577,"interventions":2579},"NCT02268357","The Effects of Propranolol on Fear of Tooth or Molar Extraction",[89,90],[2578],"Dental Anxiety",[2563],{"trials":2581,"activeCount":99},[],{"trials":2583,"activeCount":99},[],{"intervention":2585,"totalTrials":95,"cells":2586},"Mepolizumab",{"EARLY_PHASE1":2587,"PHASE1":2589,"PHASE2":2591,"PHASE3":2593,"PHASE4":2606,"NA":2608},{"trials":2588,"activeCount":99},[],{"trials":2590,"activeCount":99},[],{"trials":2592,"activeCount":99},[],{"trials":2594,"activeCount":99},[2595],{"nctId":2596,"briefTitle":2597,"status":765,"phases":2598,"primaryCompletion":2599,"completion":2600,"start":2601,"enrollment":888,"conditions":2602,"interventions":2605},"NCT01520051","Mepolizumab Treatment for Rhinovirus-induced Asthma Exacerbations",[90],"2013-12","2014-03","2012-01",[2603,2604],"Asthma","Viral Infection",[2585],{"trials":2607,"activeCount":99},[],{"trials":2609,"activeCount":99},[],{"intervention":2611,"totalTrials":95,"cells":2612},"unfractionated heparin",{"EARLY_PHASE1":2613,"PHASE1":2615,"PHASE2":2617,"PHASE3":2619,"PHASE4":2632,"NA":2634},{"trials":2614,"activeCount":99},[],{"trials":2616,"activeCount":99},[],{"trials":2618,"activeCount":99},[],{"trials":2620,"activeCount":99},[2621],{"nctId":2622,"briefTitle":2623,"status":1578,"phases":2624,"primaryCompletion":2625,"completion":2295,"start":2626,"enrollment":2627,"conditions":2628,"interventions":2631},"NCT01773083","Trial of Nebulized Heparin Versus Placebo for Inhalation Trauma",[90],"2016-10","2013-10",13,[2629,2630],"Inhalation Injury","Burn Injury",[2611],{"trials":2633,"activeCount":99},[],{"trials":2635,"activeCount":99},[],{"intervention":2637,"totalTrials":95,"cells":2638},"Standard adjuvant systemic chemotherapy",{"EARLY_PHASE1":2639,"PHASE1":2641,"PHASE2":2643,"PHASE3":2645,"PHASE4":2659,"NA":2661},{"trials":2640,"activeCount":99},[],{"trials":2642,"activeCount":99},[],{"trials":2644,"activeCount":99},[],{"trials":2646,"activeCount":99},[2647],{"nctId":2648,"briefTitle":2649,"status":333,"phases":2650,"primaryCompletion":2651,"completion":2652,"start":2653,"enrollment":2654,"conditions":2655,"interventions":2658},"NCT02231086","Adjuvant HIPEC in High Risk Colon Cancer",[90],"2018-09","2019-06-01","2015-03",204,[2656,2657],"Colorectal Neoplasms","Peritoneal Neoplasms",[2637],{"trials":2660,"activeCount":99},[],{"trials":2662,"activeCount":99},[],{"intervention":2664,"totalTrials":95,"cells":2665},"Mercaptopurine",{"EARLY_PHASE1":2666,"PHASE1":2668,"PHASE2":2670,"PHASE3":2672,"PHASE4":2684,"NA":2686},{"trials":2667,"activeCount":99},[],{"trials":2669,"activeCount":99},[],{"trials":2671,"activeCount":99},[],{"trials":2673,"activeCount":99},[2674],{"nctId":2675,"briefTitle":2676,"status":765,"phases":2677,"primaryCompletion":2678,"completion":2678,"start":2061,"enrollment":2679,"conditions":2680,"interventions":2681},"NCT02910245","Mercaptopurine Therapy in Ulcerative Colitis",[90],"2022-04-30",136,[1583],[2664,2682,2683],"Mesalamine","Prednisone",{"trials":2685,"activeCount":99},[],{"trials":2687,"activeCount":99},[],{"intervention":2682,"totalTrials":95,"cells":2689},{"EARLY_PHASE1":2690,"PHASE1":2692,"PHASE2":2694,"PHASE3":2696,"PHASE4":2702,"NA":2704},{"trials":2691,"activeCount":99},[],{"trials":2693,"activeCount":99},[],{"trials":2695,"activeCount":99},[],{"trials":2697,"activeCount":99},[2698],{"nctId":2675,"briefTitle":2676,"status":765,"phases":2699,"primaryCompletion":2678,"completion":2678,"start":2061,"enrollment":2679,"conditions":2700,"interventions":2701},[90],[1583],[2664,2682,2683],{"trials":2703,"activeCount":99},[],{"trials":2705,"activeCount":99},[],{"intervention":2683,"totalTrials":95,"cells":2707},{"EARLY_PHASE1":2708,"PHASE1":2710,"PHASE2":2712,"PHASE3":2714,"PHASE4":2720,"NA":2722},{"trials":2709,"activeCount":99},[],{"trials":2711,"activeCount":99},[],{"trials":2713,"activeCount":99},[],{"trials":2715,"activeCount":99},[2716],{"nctId":2675,"briefTitle":2676,"status":765,"phases":2717,"primaryCompletion":2678,"completion":2678,"start":2061,"enrollment":2679,"conditions":2718,"interventions":2719},[90],[1583],[2664,2682,2683],{"trials":2721,"activeCount":99},[],{"trials":2723,"activeCount":99},[],{"intervention":2725,"totalTrials":95,"cells":2726},"golimumab",{"EARLY_PHASE1":2727,"PHASE1":2729,"PHASE2":2731,"PHASE3":2733,"PHASE4":2745,"NA":2747},{"trials":2728,"activeCount":99},[],{"trials":2730,"activeCount":99},[],{"trials":2732,"activeCount":99},[],{"trials":2734,"activeCount":99},[2735],{"nctId":2736,"briefTitle":2737,"status":333,"phases":2738,"primaryCompletion":2739,"completion":2739,"start":2740,"enrollment":2323,"conditions":2741,"interventions":2743},"NCT01871649","Initial Treatment With Golimumab in Early PsA",[90],"2018-11","2013-08",[2742],"Psoriatic Arthritis",[2725,2744],"methotrexate",{"trials":2746,"activeCount":99},[],{"trials":2748,"activeCount":99},[],{"intervention":2744,"totalTrials":95,"cells":2750},{"EARLY_PHASE1":2751,"PHASE1":2753,"PHASE2":2755,"PHASE3":2757,"PHASE4":2763,"NA":2765},{"trials":2752,"activeCount":99},[],{"trials":2754,"activeCount":99},[],{"trials":2756,"activeCount":99},[],{"trials":2758,"activeCount":99},[2759],{"nctId":2736,"briefTitle":2737,"status":333,"phases":2760,"primaryCompletion":2739,"completion":2739,"start":2740,"enrollment":2323,"conditions":2761,"interventions":2762},[90],[2742],[2725,2744],{"trials":2764,"activeCount":99},[],{"trials":2766,"activeCount":99},[],{"intervention":2768,"totalTrials":95,"cells":2769},"Chlorhexidine gluconate (drug) vs placebo",{"EARLY_PHASE1":2770,"PHASE1":2772,"PHASE2":2774,"PHASE3":2776,"PHASE4":2789,"NA":2791},{"trials":2771,"activeCount":99},[],{"trials":2773,"activeCount":99},[],{"trials":2775,"activeCount":99},[],{"trials":2777,"activeCount":99},[2778],{"nctId":2779,"briefTitle":2780,"status":333,"phases":2781,"completion":1849,"start":2782,"enrollment":2783,"conditions":2784,"interventions":2788},"NCT00272675","Prevention of Nosocomial Infection by Decontamination of the Naso- and Oropharynx With Chlorhexidine (NONI Trial)",[89,90],"2003-08",1000,[2785,2786,2787],"Nosocomial Infection","Respiratory Tract Infection","Surgical Site Infection",[2768],{"trials":2790,"activeCount":99},[],{"trials":2792,"activeCount":99},[],{"intervention":2794,"totalTrials":95,"cells":2795},"N-Acetylcysteine",{"EARLY_PHASE1":2796,"PHASE1":2798,"PHASE2":2800,"PHASE3":2802,"PHASE4":2811,"NA":2813},{"trials":2797,"activeCount":99},[],{"trials":2799,"activeCount":99},[],{"trials":2801,"activeCount":99},[],{"trials":2803,"activeCount":99},[2804],{"nctId":2805,"briefTitle":2806,"status":333,"phases":2807,"primaryCompletion":1283,"completion":1283,"start":1984,"enrollment":2808,"conditions":2809,"interventions":2810},"NCT01849016","N-Acetylcysteine in Patients With Sickle Cell Disease",[90],96,[21],[2794],{"trials":2812,"activeCount":99},[],{"trials":2814,"activeCount":99},[],{"intervention":2816,"totalTrials":95,"cells":2817},"Secukinumab",{"EARLY_PHASE1":2818,"PHASE1":2820,"PHASE2":2822,"PHASE3":2824,"PHASE4":2836,"NA":2838},{"trials":2819,"activeCount":99},[],{"trials":2821,"activeCount":99},[],{"trials":2823,"activeCount":99},[],{"trials":2825,"activeCount":99},[2826],{"nctId":2827,"briefTitle":2828,"status":333,"phases":2829,"primaryCompletion":2830,"completion":2831,"start":2600,"enrollment":2832,"conditions":2833,"interventions":2835},"NCT03358134","Mechanism of Action of Anti-IL17 Therapy in Peripheral Spondyloarthritis",[90],"2017-07","2017-10",20,[2834],"Spondylarthropathies",[2816],{"trials":2837,"activeCount":99},[],{"trials":2839,"activeCount":99},[],{"intervention":774,"totalTrials":1244,"cells":2841},{"EARLY_PHASE1":2842,"PHASE1":2844,"PHASE2":2846,"PHASE3":2866,"PHASE4":2868,"NA":2870},{"trials":2843,"activeCount":99},[],{"trials":2845,"activeCount":99},[],{"trials":2847,"activeCount":99},[2848,2852,2862],{"nctId":763,"briefTitle":764,"status":765,"phases":2849,"primaryCompletion":767,"completion":768,"start":769,"enrollment":770,"conditions":2850,"interventions":2851},[88,89],[772],[774,326],{"nctId":2853,"briefTitle":2854,"status":2855,"phases":2856,"primaryCompletion":419,"completion":419,"start":2857,"enrollment":99,"conditions":2858,"interventions":2861},"NCT01178151","Study of Everolimus in the Treatment of Advanced Malignancies in Patients With Peutz-Jeghers Syndrome","WITHDRAWN",[89],"2010-10",[2859,2860,424],"Peutz-Jeghers Syndrome","Neoplastic Processes",[774],{"nctId":790,"briefTitle":791,"status":333,"phases":2863,"primaryCompletion":793,"completion":794,"start":795,"enrollment":770,"conditions":2864,"interventions":2865},[88,89],[797],[326,799,774],{"trials":2867,"activeCount":99},[],{"trials":2869,"activeCount":99},[],{"trials":2871,"activeCount":99},[],{"intervention":2873,"totalTrials":95,"cells":2874},"Dasatinib",{"EARLY_PHASE1":2875,"PHASE1":2877,"PHASE2":2879,"PHASE3":2890,"PHASE4":2892,"NA":2894},{"trials":2876,"activeCount":99},[],{"trials":2878,"activeCount":99},[],{"trials":2880,"activeCount":99},[2881],{"nctId":2882,"briefTitle":2883,"status":765,"phases":2884,"primaryCompletion":2037,"completion":2885,"start":2886,"enrollment":770,"conditions":2887,"interventions":2889},"NCT01051115","Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease",[89],"2016-01","2008-10",[2888],"Chronic Lymphocytic Leukemia",[2873],{"trials":2891,"activeCount":99},[],{"trials":2893,"activeCount":99},[],{"trials":2895,"activeCount":99},[],{"intervention":1263,"totalTrials":95,"cells":2897},{"EARLY_PHASE1":2898,"PHASE1":2900,"PHASE2":2902,"PHASE3":2908,"PHASE4":2910,"NA":2912},{"trials":2899,"activeCount":99},[],{"trials":2901,"activeCount":99},[],{"trials":2903,"activeCount":99},[2904],{"nctId":1253,"briefTitle":1254,"status":333,"phases":2905,"primaryCompletion":1256,"completion":1257,"start":793,"enrollment":1258,"conditions":2906,"interventions":2907},[89],[1260,797],[1262,1263,1264],{"trials":2909,"activeCount":99},[],{"trials":2911,"activeCount":99},[],{"trials":2913,"activeCount":99},[],{"intervention":2915,"totalTrials":95,"cells":2916},"ascorbic acid",{"EARLY_PHASE1":2917,"PHASE1":2919,"PHASE2":2921,"PHASE3":2933,"PHASE4":2935,"NA":2937},{"trials":2918,"activeCount":99},[],{"trials":2920,"activeCount":99},[],{"trials":2922,"activeCount":99},[2923],{"nctId":2924,"briefTitle":2925,"status":333,"phases":2926,"primaryCompletion":2927,"completion":2927,"start":2928,"enrollment":2627,"conditions":2929,"interventions":2932},"NCT00271635","Ascorbic Acid Treatment in CMT1A Trial (AATIC)",[89],"2007-07","2006-01",[2930,2931],"Charcot-Marie-Tooth Disease","Hereditary Motor and Sensory Neuropathies",[2915],{"trials":2934,"activeCount":99},[],{"trials":2936,"activeCount":99},[],{"trials":2938,"activeCount":99},[],{"intervention":2940,"totalTrials":95,"cells":2941},"Bosentan",{"EARLY_PHASE1":2942,"PHASE1":2944,"PHASE2":2946,"PHASE3":2959,"PHASE4":2961,"NA":2963},{"trials":2943,"activeCount":99},[],{"trials":2945,"activeCount":99},[],{"trials":2947,"activeCount":99},[2948],{"nctId":2949,"briefTitle":2950,"status":765,"phases":2951,"primaryCompletion":2952,"completion":2953,"start":2626,"enrollment":2954,"conditions":2955,"interventions":2958},"NCT01827059","Bosentan In Exercise Induced Pulmonary Arterial Hypertension in CongenitaL Heart diseasE",[89],"2018-02","2018-06",12,[2956,2957],"Pulmonary Arterial Hypertension","Congenital Heart Disease",[2940],{"trials":2960,"activeCount":99},[],{"trials":2962,"activeCount":99},[],{"trials":2964,"activeCount":99},[],{"intervention":2966,"totalTrials":95,"cells":2967},"Prasugrel 10mg",{"EARLY_PHASE1":2968,"PHASE1":2970,"PHASE2":2972,"PHASE3":2985,"PHASE4":2987,"NA":2989},{"trials":2969,"activeCount":99},[],{"trials":2971,"activeCount":99},[],{"trials":2973,"activeCount":99},[2974],{"nctId":2975,"briefTitle":2976,"status":333,"phases":2977,"primaryCompletion":2978,"completion":2979,"start":2980,"enrollment":2981,"conditions":2982,"interventions":2983},"NCT04766437","Optical Coherence Tomography-Guided PCI With Single-Antiplatelet Therapy",[89],"2022-09-03","2023-03-03","2021-02-19",75,[1895],[2966,2984],"Ticagrelor 90mg",{"trials":2986,"activeCount":99},[],{"trials":2988,"activeCount":99},[],{"trials":2990,"activeCount":99},[],{"intervention":2984,"totalTrials":95,"cells":2992},{"EARLY_PHASE1":2993,"PHASE1":2995,"PHASE2":2997,"PHASE3":3003,"PHASE4":3005,"NA":3007},{"trials":2994,"activeCount":99},[],{"trials":2996,"activeCount":99},[],{"trials":2998,"activeCount":99},[2999],{"nctId":2975,"briefTitle":2976,"status":333,"phases":3000,"primaryCompletion":2978,"completion":2979,"start":2980,"enrollment":2981,"conditions":3001,"interventions":3002},[89],[1895],[2966,2984],{"trials":3004,"activeCount":99},[],{"trials":3006,"activeCount":99},[],{"trials":3008,"activeCount":99},[],{"intervention":3010,"totalTrials":95,"cells":3011},"Lithium Carbonate",{"EARLY_PHASE1":3012,"PHASE1":3014,"PHASE2":3016,"PHASE3":3027,"PHASE4":3029,"NA":3031},{"trials":3013,"activeCount":99},[],{"trials":3015,"activeCount":99},[],{"trials":3017,"activeCount":99},[3018],{"nctId":3019,"briefTitle":3020,"status":333,"phases":3021,"primaryCompletion":3022,"completion":3022,"start":3023,"enrollment":2954,"conditions":3024,"interventions":3026},"NCT05402891","The CHAMP-study: The CHemopreventive Effect of Lithium in Familial AdenoMatous Polyposis",[89],"2024-09-30","2022-06-02",[3025],"Familial Adenomatous Polyposis",[3010],{"trials":3028,"activeCount":99},[],{"trials":3030,"activeCount":99},[],{"trials":3032,"activeCount":99},[],{"intervention":3034,"totalTrials":95,"cells":3035},"Losartan",{"EARLY_PHASE1":3036,"PHASE1":3038,"PHASE2":3040,"PHASE3":3052,"PHASE4":3054,"NA":3056},{"trials":3037,"activeCount":99},[],{"trials":3039,"activeCount":99},[],{"trials":3041,"activeCount":99},[3042],{"nctId":3043,"briefTitle":3044,"status":765,"phases":3045,"primaryCompletion":3046,"completion":3046,"start":2599,"enrollment":1258,"conditions":3047,"interventions":3051},"NCT02010905","Right Ventricular Dysfunction in Tetralogy of Fallot: Inhibition of the Renin-angiotensin-aldosterone System",[89],"2018-01",[3048,3049,3050],"Tetralogy of Fallot","Heart Defects, Congenital","Ventricular Dysfunction, Right",[3034],{"trials":3053,"activeCount":99},[],{"trials":3055,"activeCount":99},[],{"trials":3057,"activeCount":99},[],{"intervention":3059,"totalTrials":95,"cells":3060},"Quinidine",{"EARLY_PHASE1":3061,"PHASE1":3063,"PHASE2":3065,"PHASE3":3076,"PHASE4":3078,"NA":3080},{"trials":3062,"activeCount":99},[],{"trials":3064,"activeCount":99},[],{"trials":3066,"activeCount":99},[3067],{"nctId":3068,"briefTitle":3069,"status":765,"phases":3070,"primaryCompletion":290,"completion":186,"start":213,"enrollment":3071,"conditions":3072,"interventions":3074},"NCT05593757","Quinidine Versus Verapamil in Short-coupled Idiopathic Ventricular Fibrillation",[89],24,[3073],"Short-coupled Idiopathic Ventricular Fibrillation",[3059,3075],"Verapamil",{"trials":3077,"activeCount":99},[],{"trials":3079,"activeCount":99},[],{"trials":3081,"activeCount":99},[],{"intervention":3075,"totalTrials":95,"cells":3083},{"EARLY_PHASE1":3084,"PHASE1":3086,"PHASE2":3088,"PHASE3":3094,"PHASE4":3096,"NA":3098},{"trials":3085,"activeCount":99},[],{"trials":3087,"activeCount":99},[],{"trials":3089,"activeCount":99},[3090],{"nctId":3068,"briefTitle":3069,"status":765,"phases":3091,"primaryCompletion":290,"completion":186,"start":213,"enrollment":3071,"conditions":3092,"interventions":3093},[89],[3073],[3059,3075],{"trials":3095,"activeCount":99},[],{"trials":3097,"activeCount":99},[],{"trials":3099,"activeCount":99},[],{"intervention":3101,"totalTrials":95,"cells":3102},"Dasatinib 100 MG + Quercetin",{"EARLY_PHASE1":3103,"PHASE1":3105,"PHASE2":3107,"PHASE3":3120,"PHASE4":3122,"NA":3124},{"trials":3104,"activeCount":99},[],{"trials":3106,"activeCount":99},[],{"trials":3108,"activeCount":99},[3109],{"nctId":3110,"briefTitle":3111,"status":333,"phases":3112,"primaryCompletion":3113,"completion":3113,"start":3114,"enrollment":237,"conditions":3115,"interventions":3119},"NCT05506488","Dasatinib and Quercetin to Treat Fibrotic Non-alcoholic Fatty Liver Disease",[88,89],"2026-02-26","2023-07-05",[3116,3117,3118],"NAFLD","NASH With Fibrosis","Liver Fibrosis",[3101],{"trials":3121,"activeCount":99},[],{"trials":3123,"activeCount":99},[],{"trials":3125,"activeCount":99},[],{"intervention":3127,"totalTrials":95,"cells":3128},"Lidocaine IV",{"EARLY_PHASE1":3129,"PHASE1":3131,"PHASE2":3133,"PHASE3":3145,"PHASE4":3147,"NA":3149},{"trials":3130,"activeCount":99},[],{"trials":3132,"activeCount":99},[],{"trials":3134,"activeCount":99},[3135],{"nctId":3136,"briefTitle":3137,"status":333,"phases":3138,"primaryCompletion":3139,"completion":3139,"start":3140,"enrollment":237,"conditions":3141,"interventions":3144},"NCT05906615","Intravenous Lidocaine for Pain Associated With Pancreatic Cancer and Chronic Pancreatitis",[89],"2023-07-01","2021-01-14",[3142,3143],"Pancreatic Cancer","Chronic Pancreatitis",[3127],{"trials":3146,"activeCount":99},[],{"trials":3148,"activeCount":99},[],{"trials":3150,"activeCount":99},[],{"intervention":3152,"totalTrials":95,"cells":3153},"Nab-paclitaxel",{"EARLY_PHASE1":3154,"PHASE1":3156,"PHASE2":3158,"PHASE3":3169,"PHASE4":3171,"NA":3173},{"trials":3155,"activeCount":99},[],{"trials":3157,"activeCount":99},[],{"trials":3159,"activeCount":99},[3160],{"nctId":3161,"briefTitle":3162,"status":333,"phases":3163,"primaryCompletion":3164,"completion":3164,"start":1985,"enrollment":3165,"conditions":3166,"interventions":3168},"NCT02273713","The Addition of Nab-paclitaxel (Abraxane) to First Line Treatment of Metastasized Oesophagogastric Carcinoma (ACTION)",[88,89],"2017-03",154,[18,3167],"Toxicity",[3152],{"trials":3170,"activeCount":99},[],{"trials":3172,"activeCount":99},[],{"trials":3174,"activeCount":99},[],{"intervention":3176,"totalTrials":95,"cells":3177},"2-Iminobiotin",{"EARLY_PHASE1":3178,"PHASE1":3180,"PHASE2":3182,"PHASE3":3194,"PHASE4":3196,"NA":3198},{"trials":3179,"activeCount":99},[],{"trials":3181,"activeCount":99},[],{"trials":3183,"activeCount":99},[3184],{"nctId":3185,"briefTitle":3186,"status":1578,"phases":3187,"primaryCompletion":2415,"completion":3188,"start":1654,"enrollment":3189,"conditions":3190,"interventions":3193},"NCT02836340","TIBOHCA: Safety, Tolerability and Pharmacokinetics of 2-Iminobiotin (2-IB) After OHCA",[88,89],"2020-04",21,[3191,3192],"Cardiac Arrest","Hypoxic Ischemic Brain Injury",[3176],{"trials":3195,"activeCount":99},[],{"trials":3197,"activeCount":99},[],{"trials":3199,"activeCount":99},[],{"intervention":3201,"totalTrials":95,"cells":3202},"Sirolimus",{"EARLY_PHASE1":3203,"PHASE1":3205,"PHASE2":3207,"PHASE3":3218,"PHASE4":3220,"NA":3222},{"trials":3204,"activeCount":99},[],{"trials":3206,"activeCount":99},[],{"trials":3208,"activeCount":99},[3209],{"nctId":3210,"briefTitle":3211,"status":333,"phases":3212,"primaryCompletion":3213,"completion":3213,"start":3214,"enrollment":754,"conditions":3215,"interventions":3217},"NCT03095703","Sirolimus and Familial Adenomatous Polyposis (FAP)",[89],"2018-12-10","2017-10-03",[3216],"Adenomatous Polyposis Coli",[3201],{"trials":3219,"activeCount":99},[],{"trials":3221,"activeCount":99},[],{"trials":3223,"activeCount":99},[],{"intervention":3225,"totalTrials":95,"cells":3226},"HPV-16 vaccine",{"EARLY_PHASE1":3227,"PHASE1":3229,"PHASE2":3231,"PHASE3":3242,"PHASE4":3244,"NA":3246},{"trials":3228,"activeCount":99},[],{"trials":3230,"activeCount":99},[],{"trials":3232,"activeCount":99},[3233],{"nctId":3234,"briefTitle":3235,"status":333,"phases":3236,"primaryCompletion":3237,"completion":2295,"start":2740,"enrollment":113,"conditions":3238,"interventions":3241},"NCT01923116","Therapeutic HPV-16 Vaccination for the Treatment of Anal Dysplasia",[88,89],"2017-06",[3239,3240],"Anal Intraepithelial Neoplasia","HIV",[3225],{"trials":3243,"activeCount":99},[],{"trials":3245,"activeCount":99},[],{"trials":3247,"activeCount":99},[],{"intervention":341,"totalTrials":95,"cells":3249},{"EARLY_PHASE1":3250,"PHASE1":3252,"PHASE2":3254,"PHASE3":3260,"PHASE4":3262,"NA":3264},{"trials":3251,"activeCount":99},[],{"trials":3253,"activeCount":99},[],{"trials":3255,"activeCount":99},[3256],{"nctId":331,"briefTitle":332,"status":333,"phases":3257,"primaryCompletion":335,"completion":335,"start":336,"enrollment":113,"conditions":3258,"interventions":3259},[89],[338,339],[341,307,342],{"trials":3261,"activeCount":99},[],{"trials":3263,"activeCount":99},[],{"trials":3265,"activeCount":99},[],{"intervention":3267,"totalTrials":95,"cells":3268},"S1 + Nal-IRI",{"EARLY_PHASE1":3269,"PHASE1":3271,"PHASE2":3273,"PHASE3":3285,"PHASE4":3287,"NA":3289},{"trials":3270,"activeCount":99},[],{"trials":3272,"activeCount":99},[],{"trials":3274,"activeCount":99},[3275],{"nctId":3276,"briefTitle":3277,"status":765,"phases":3278,"primaryCompletion":3279,"completion":3279,"start":3280,"enrollment":3281,"conditions":3282,"interventions":3283},"NCT03986294","Second Line Treatment With Nal-IRI and S1 in Pancreatic Cancer",[89],"2022-01-01","2019-12-01",122,[797],[3267,3284],"Nal-IRI+Leucovorin+5-FU",{"trials":3286,"activeCount":99},[],{"trials":3288,"activeCount":99},[],{"trials":3290,"activeCount":99},[],{"intervention":3284,"totalTrials":95,"cells":3292},{"EARLY_PHASE1":3293,"PHASE1":3295,"PHASE2":3297,"PHASE3":3303,"PHASE4":3305,"NA":3307},{"trials":3294,"activeCount":99},[],{"trials":3296,"activeCount":99},[],{"trials":3298,"activeCount":99},[3299],{"nctId":3276,"briefTitle":3277,"status":765,"phases":3300,"primaryCompletion":3279,"completion":3279,"start":3280,"enrollment":3281,"conditions":3301,"interventions":3302},[89],[797],[3267,3284],{"trials":3304,"activeCount":99},[],{"trials":3306,"activeCount":99},[],{"trials":3308,"activeCount":99},[],{"intervention":3310,"totalTrials":95,"cells":3311},"Nanocort",{"EARLY_PHASE1":3312,"PHASE1":3314,"PHASE2":3316,"PHASE3":3327,"PHASE4":3329,"NA":3331},{"trials":3313,"activeCount":99},[],{"trials":3315,"activeCount":99},[],{"trials":3317,"activeCount":99},[3318],{"nctId":3319,"briefTitle":3320,"status":765,"phases":3321,"primaryCompletion":3322,"completion":3322,"start":3323,"enrollment":3189,"conditions":3324,"interventions":3325},"NCT01647685","A Proof of Concept Study to Determine the Local Delivery and Efficacy of Nanocort",[88,89],"2013-05","2012-05",[642],[3310,3326],"Methylprednisolone",{"trials":3328,"activeCount":99},[],{"trials":3330,"activeCount":99},[],{"trials":3332,"activeCount":99},[],{"intervention":3326,"totalTrials":95,"cells":3334},{"EARLY_PHASE1":3335,"PHASE1":3337,"PHASE2":3339,"PHASE3":3345,"PHASE4":3347,"NA":3349},{"trials":3336,"activeCount":99},[],{"trials":3338,"activeCount":99},[],{"trials":3340,"activeCount":99},[3341],{"nctId":3319,"briefTitle":3320,"status":765,"phases":3342,"primaryCompletion":3322,"completion":3322,"start":3323,"enrollment":3189,"conditions":3343,"interventions":3344},[88,89],[642],[3310,3326],{"trials":3346,"activeCount":99},[],{"trials":3348,"activeCount":99},[],{"trials":3350,"activeCount":99},[],{"intervention":3352,"totalTrials":95,"cells":3353},"liposomal prednisolone",{"EARLY_PHASE1":3354,"PHASE1":3356,"PHASE2":3358,"PHASE3":3367,"PHASE4":3369,"NA":3371},{"trials":3355,"activeCount":99},[],{"trials":3357,"activeCount":99},[],{"trials":3359,"activeCount":99},[3360],{"nctId":3361,"briefTitle":3362,"status":765,"phases":3363,"primaryCompletion":3322,"start":3364,"enrollment":237,"conditions":3365,"interventions":3366},"NCT01601106","Silencing Inflammatory Activity by Injecting Nanocort in Patients at Risk for Atherosclerotic Disease",[88,89],"2011-09",[642,643],[3352],{"trials":3368,"activeCount":99},[],{"trials":3370,"activeCount":99},[],{"trials":3372,"activeCount":99},[],{"intervention":3374,"totalTrials":95,"cells":3375},"gemcitabine and nab paclitaxel",{"EARLY_PHASE1":3376,"PHASE1":3378,"PHASE2":3380,"PHASE3":3390,"PHASE4":3392,"NA":3394},{"trials":3377,"activeCount":99},[],{"trials":3379,"activeCount":99},[],{"trials":3381,"activeCount":99},[3382],{"nctId":3383,"briefTitle":3384,"status":333,"phases":3385,"primaryCompletion":2651,"completion":3386,"start":3387,"enrollment":350,"conditions":3388,"interventions":3389},"NCT02358161","Phase I\u002FII Study of LDE225 With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer",[88,89],"2019-01","2015-09",[3142],[3374],{"trials":3391,"activeCount":99},[],{"trials":3393,"activeCount":99},[],{"trials":3395,"activeCount":99},[],{"intervention":3397,"totalTrials":95,"cells":3398},"Pertuzumab, trastuzumab",{"EARLY_PHASE1":3399,"PHASE1":3401,"PHASE2":3403,"PHASE3":3413,"PHASE4":3415,"NA":3417},{"trials":3400,"activeCount":99},[],{"trials":3402,"activeCount":99},[],{"trials":3404,"activeCount":99},[3405],{"nctId":3406,"briefTitle":3407,"status":333,"phases":3408,"primaryCompletion":3409,"completion":3409,"start":3410,"enrollment":113,"conditions":3411,"interventions":3412},"NCT02120911","Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+ Esophageal Carcinoma",[88,89],"2017-02","2014-01",[468],[3397],{"trials":3414,"activeCount":99},[],{"trials":3416,"activeCount":99},[],{"trials":3418,"activeCount":99},[],{"intervention":3420,"totalTrials":95,"cells":3421},"Metformin and chloroquine combination",{"EARLY_PHASE1":3422,"PHASE1":3424,"PHASE2":3426,"PHASE3":3440,"PHASE4":3442,"NA":3444},{"trials":3423,"activeCount":99},[],{"trials":3425,"activeCount":99},[],{"trials":3427,"activeCount":99},[3428],{"nctId":3429,"briefTitle":3430,"status":333,"phases":3431,"primaryCompletion":3432,"completion":3432,"start":3433,"enrollment":3434,"conditions":3435,"interventions":3439},"NCT02496741","Metformin And Chloroquine in IDH1\u002F2-mutated Solid Tumors",[88,89],"2019-11-18","2015-11",15,[3436,3437,3438],"Glioma","Cholangiocarcinoma","Chondrosarcoma",[3420],{"trials":3441,"activeCount":99},[],{"trials":3443,"activeCount":99},[],{"trials":3445,"activeCount":99},[],{"intervention":3447,"totalTrials":95,"cells":3448},"Sorafenib",{"EARLY_PHASE1":3449,"PHASE1":3451,"PHASE2":3453,"PHASE3":3465,"PHASE4":3467,"NA":3469},{"trials":3450,"activeCount":99},[],{"trials":3452,"activeCount":99},[],{"trials":3454,"activeCount":99},[3455],{"nctId":3456,"briefTitle":3457,"status":1578,"phases":3458,"primaryCompletion":3164,"completion":3164,"start":3459,"enrollment":3460,"conditions":3461,"interventions":3464},"NCT04051853","Sorafenib PK in Patients With Advanced HCC and Child-Pugh B",[89],"2014-05",5,[3462,3463],"BCLC Stage C HCC","CP-B Liver Cirrhosis",[3447],{"trials":3466,"activeCount":99},[],{"trials":3468,"activeCount":99},[],{"trials":3470,"activeCount":99},[],{"intervention":356,"totalTrials":95,"cells":3472},{"EARLY_PHASE1":3473,"PHASE1":3475,"PHASE2":3477,"PHASE3":3483,"PHASE4":3485,"NA":3487},{"trials":3474,"activeCount":99},[],{"trials":3476,"activeCount":99},[],{"trials":3478,"activeCount":99},[3479],{"nctId":344,"briefTitle":345,"status":333,"phases":3480,"primaryCompletion":347,"completion":348,"start":349,"enrollment":350,"conditions":3481,"interventions":3482},[89],[352,353,18,354],[307,342,356],{"trials":3484,"activeCount":99},[],{"trials":3486,"activeCount":99},[],{"trials":3488,"activeCount":99},[],{"intervention":799,"totalTrials":95,"cells":3490},{"EARLY_PHASE1":3491,"PHASE1":3493,"PHASE2":3495,"PHASE3":3501,"PHASE4":3503,"NA":3505},{"trials":3492,"activeCount":99},[],{"trials":3494,"activeCount":99},[],{"trials":3496,"activeCount":99},[3497],{"nctId":790,"briefTitle":791,"status":333,"phases":3498,"primaryCompletion":793,"completion":794,"start":795,"enrollment":770,"conditions":3499,"interventions":3500},[88,89],[797],[326,799,774],{"trials":3502,"activeCount":99},[],{"trials":3504,"activeCount":99},[],{"trials":3506,"activeCount":99},[],{"intervention":3508,"totalTrials":95,"cells":3509},"cisplatin",{"EARLY_PHASE1":3510,"PHASE1":3512,"PHASE2":3514,"PHASE3":3524,"PHASE4":3526,"NA":3528},{"trials":3511,"activeCount":99},[],{"trials":3513,"activeCount":99},[],{"trials":3515,"activeCount":99},[3516],{"nctId":3517,"briefTitle":3518,"status":765,"phases":3519,"start":3520,"conditions":3521,"interventions":3523},"NCT00008112","Cisplatin Combined With Radiation Therapy and Hyperthermia in Treating Patients With Stage II, Stage III, or Stage IV Cervical Cancer",[89],"2000-06",[3522],"Cervical Cancer",[3508],{"trials":3525,"activeCount":99},[],{"trials":3527,"activeCount":99},[],{"trials":3529,"activeCount":99},[],{"intervention":3531,"totalTrials":95,"cells":3532},"Vericiguat",{"EARLY_PHASE1":3533,"PHASE1":3535,"PHASE2":3537,"PHASE3":3548,"PHASE4":3550,"NA":3552},{"trials":3534,"activeCount":99},[],{"trials":3536,"activeCount":99},[],{"trials":3538,"activeCount":99},[3539],{"nctId":3540,"briefTitle":3541,"status":765,"phases":3542,"primaryCompletion":3543,"completion":3543,"start":79,"enrollment":3544,"conditions":3545,"interventions":3547},"NCT06415227","The Impact of Vericiguat on Microvascular Function in Patients with Documented Vasospastic Angina Pectoris",[89],"2026-06-01",55,[3546],"Vasospastic Angina",[3531],{"trials":3549,"activeCount":99},[],{"trials":3551,"activeCount":99},[],{"trials":3553,"activeCount":99},[],{"intervention":3555,"totalTrials":95,"cells":3556},"Deferasirox 360 MG",{"EARLY_PHASE1":3557,"PHASE1":3559,"PHASE2":3561,"PHASE3":3572,"PHASE4":3574,"NA":3576},{"trials":3558,"activeCount":99},[],{"trials":3560,"activeCount":99},[],{"trials":3562,"activeCount":99},[3563],{"nctId":3564,"briefTitle":3565,"status":333,"phases":3566,"primaryCompletion":3567,"completion":3568,"start":3569,"enrollment":2954,"conditions":3570,"interventions":3571},"NCT05392101","Low Dose Iron Chelation as TReatment of Oxidative Damage in Sickle Cell Disease",[89],"2022-08-20","2022-11-20","2021-07-20",[21],[3555],{"trials":3573,"activeCount":99},[],{"trials":3575,"activeCount":99},[],{"trials":3577,"activeCount":99},[],{"intervention":426,"totalTrials":95,"cells":3579},{"EARLY_PHASE1":3580,"PHASE1":3582,"PHASE2":3584,"PHASE3":3590,"PHASE4":3592,"NA":3594},{"trials":3581,"activeCount":99},[],{"trials":3583,"activeCount":99},[],{"trials":3585,"activeCount":99},[3586],{"nctId":415,"briefTitle":416,"status":333,"phases":3587,"primaryCompletion":418,"completion":418,"start":419,"enrollment":420,"conditions":3588,"interventions":3589},[88,89],[422,423,424],[426,342],{"trials":3591,"activeCount":99},[],{"trials":3593,"activeCount":99},[],{"trials":3595,"activeCount":99},[],{"intervention":3597,"totalTrials":95,"cells":3598},"S-1 and Oxaliplatin",{"EARLY_PHASE1":3599,"PHASE1":3601,"PHASE2":3610,"PHASE3":3612,"PHASE4":3614,"NA":3616},{"trials":3600,"activeCount":99},[],{"trials":3602,"activeCount":99},[3603],{"nctId":3604,"briefTitle":3605,"status":333,"phases":3606,"primaryCompletion":2414,"completion":2414,"start":3607,"enrollment":113,"conditions":3608,"interventions":3609},"NCT02347904","Feasibility Study of Adjuvant Treatment With S-1 and Oxaliplatin in Patients With Resectable Esophageal Cancer",[88],"2014-12",[18],[3597],{"trials":3611,"activeCount":99},[],{"trials":3613,"activeCount":99},[],{"trials":3615,"activeCount":99},[],{"trials":3617,"activeCount":99},[],{"intervention":3619,"totalTrials":95,"cells":3620},"Anti-PD-1 antibody balstilimab",{"EARLY_PHASE1":3621,"PHASE1":3623,"PHASE2":3632,"PHASE3":3634,"PHASE4":3636,"NA":3638},{"trials":3622,"activeCount":99},[],{"trials":3624,"activeCount":99},[3625],{"nctId":3626,"briefTitle":3627,"status":765,"phases":3628,"primaryCompletion":964,"completion":964,"start":3629,"enrollment":237,"conditions":3630,"interventions":3631},"NCT06095674","ImmunoTHerapy Adjacent to Cervical CAncer (ITHACA) Study",[88],"2024-01",[3522],[3619],{"trials":3633,"activeCount":99},[],{"trials":3635,"activeCount":99},[],{"trials":3637,"activeCount":99},[],{"trials":3639,"activeCount":99},[],{"intervention":3641,"totalTrials":95,"cells":3642},"ConM SOSIP.v7 gp140, adjuvanted with MPLA liposomes",{"EARLY_PHASE1":3643,"PHASE1":3645,"PHASE2":3657,"PHASE3":3659,"PHASE4":3661,"NA":3663},{"trials":3644,"activeCount":99},[],{"trials":3646,"activeCount":99},[3647],{"nctId":3648,"briefTitle":3649,"status":333,"phases":3650,"primaryCompletion":3651,"completion":3652,"start":3653,"enrollment":3071,"conditions":3654,"interventions":3656},"NCT03961438","Amsterdam UMC Clinical Trial With a Native-like HIV-1 Envelope Vaccine",[88],"2022-06-06","2023-04-17","2019-11-15",[3655],"HIV-1-infection",[3641,3641],{"trials":3658,"activeCount":99},[],{"trials":3660,"activeCount":99},[],{"trials":3662,"activeCount":99},[],{"trials":3664,"activeCount":99},[],{"intervention":3666,"totalTrials":95,"cells":3667},"Nelfinavir and temsirolimus",{"EARLY_PHASE1":3668,"PHASE1":3670,"PHASE2":3682,"PHASE3":3684,"PHASE4":3686,"NA":3688},{"trials":3669,"activeCount":99},[],{"trials":3671,"activeCount":99},[3672],{"nctId":3673,"briefTitle":3674,"status":333,"phases":3675,"primaryCompletion":3676,"completion":794,"start":3677,"enrollment":1285,"conditions":3678,"interventions":3681},"NCT01079286","Study of Nelfinavir and Temsirolimus in Patients With Advanced Cancers",[88],"2011-05","2009-06",[3679,3680],"Renal Cell Cancer","Cancer",[3666],{"trials":3683,"activeCount":99},[],{"trials":3685,"activeCount":99},[],{"trials":3687,"activeCount":99},[],{"trials":3689,"activeCount":99},[],{"intervention":3691,"totalTrials":1244,"cells":3692},"Gemcitabine",{"EARLY_PHASE1":3693,"PHASE1":3695,"PHASE2":3697,"PHASE3":3703,"PHASE4":3705,"NA":3707},{"trials":3694,"activeCount":99},[],{"trials":3696,"activeCount":99},[],{"trials":3698,"activeCount":99},[3699],{"nctId":1253,"briefTitle":1254,"status":333,"phases":3700,"primaryCompletion":1256,"completion":1257,"start":793,"enrollment":1258,"conditions":3701,"interventions":3702},[89],[1260,797],[1262,1263,1264],{"trials":3704,"activeCount":99},[],{"trials":3706,"activeCount":99},[],{"trials":3708,"activeCount":99},[3709,3720],{"nctId":3710,"briefTitle":3711,"status":765,"phases":3712,"primaryCompletion":2414,"completion":3713,"start":3714,"enrollment":3715,"conditions":3716,"interventions":3717},"NCT03690323","Pancreatic Locally Advanced Irresectable Cancer Ablation",[92],"2020-05","2015-04-07",228,[1260],[3718,3719,3691],"FOLFIRINOX","Nab-paclitaxel plus Gemcitabine",{"nctId":3721,"briefTitle":3722,"status":333,"phases":3723,"primaryCompletion":2295,"completion":2295,"start":3724,"enrollment":420,"conditions":3725,"interventions":3726},"NCT01989000","The Role of the Tumor Microenvironment of Pancreatic Cancer to Predict Treatment Outcome",[92],"2013-11",[3142],[3727,3728,3691],"Gadobutrol","[F-18]HX4",{"intervention":3718,"totalTrials":1244,"cells":3730},{"EARLY_PHASE1":3731,"PHASE1":3733,"PHASE2":3735,"PHASE3":3746,"PHASE4":3759,"NA":3761},{"trials":3732,"activeCount":99},[],{"trials":3734,"activeCount":99},[],{"trials":3736,"activeCount":99},[3737],{"nctId":3738,"briefTitle":3739,"status":333,"phases":3740,"primaryCompletion":3741,"completion":3742,"start":3743,"enrollment":237,"conditions":3744,"interventions":3745},"NCT02456714","Second Line Chemotherapy FOLFIRINOX in Irresectable Cholangiocarcinoma",[89],"2018-10-01","2018-12-01","2016-05-31",[3437],[3718],{"trials":3747,"activeCount":99},[3748],{"nctId":3749,"briefTitle":3750,"status":765,"phases":3751,"primaryCompletion":3752,"completion":3752,"start":3753,"enrollment":3754,"conditions":3755,"interventions":3757},"NCT04897854","Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer",[90],"2024-04-22","2021-04-22",184,[3756],"Metastatic Pancreas Cancer",[3758],"Folfirinox",{"trials":3760,"activeCount":99},[],{"trials":3762,"activeCount":99},[3763],{"nctId":3710,"briefTitle":3711,"status":765,"phases":3764,"primaryCompletion":2414,"completion":3713,"start":3714,"enrollment":3715,"conditions":3765,"interventions":3766},[92],[1260],[3718,3719,3691],{"intervention":3768,"totalTrials":367,"cells":3769},"Bromocriptine",{"EARLY_PHASE1":3770,"PHASE1":3772,"PHASE2":3774,"PHASE3":3776,"PHASE4":3778,"NA":3780},{"trials":3771,"activeCount":99},[],{"trials":3773,"activeCount":99},[],{"trials":3775,"activeCount":99},[],{"trials":3777,"activeCount":99},[],{"trials":3779,"activeCount":99},[],{"trials":3781,"activeCount":99},[3782,3788],{"nctId":3783,"briefTitle":3784,"status":333,"phases":3785,"primaryCompletion":1256,"completion":1256,"start":2626,"enrollment":22,"conditions":3786,"interventions":3787},"NCT02428933","Dopaminergic Effects on Brown Adipose Tissue",[92],[1287],[3768],{"nctId":3789,"briefTitle":3790,"status":333,"phases":3791,"primaryCompletion":3433,"completion":3792,"start":1985,"enrollment":3434,"conditions":3793,"interventions":3795},"NCT02428946","Bromocriptine and Insulin Sensitivity",[92],"2015-12",[3794],"Insulin Sensitivity",[3768],{"intervention":3797,"totalTrials":367,"cells":3798},"SonoVue",{"EARLY_PHASE1":3799,"PHASE1":3801,"PHASE2":3803,"PHASE3":3805,"PHASE4":3807,"NA":3809},{"trials":3800,"activeCount":99},[],{"trials":3802,"activeCount":99},[],{"trials":3804,"activeCount":99},[],{"trials":3806,"activeCount":99},[],{"trials":3808,"activeCount":99},[],{"trials":3810,"activeCount":99},[3811,3819],{"nctId":3812,"briefTitle":3813,"status":1578,"phases":3814,"primaryCompletion":3433,"completion":3433,"start":3815,"enrollment":3816,"conditions":3817,"interventions":3818},"NCT01481441","Quantification of Contrast Enhanced Ultrasound (CEUS) in the Detection of Prostate Cancer",[92],"2011-11",208,[15],[3797],{"nctId":3820,"briefTitle":3821,"status":765,"phases":3822,"primaryCompletion":3823,"completion":3823,"start":3824,"enrollment":188,"conditions":3825,"interventions":3827},"NCT03101176","Multiparametric Ultrasound Imaging in Prostate Cancer",[92],"2022-09-01","2017-09-07",[15,3826],"Prostatic Neoplasms",[3797],{"intervention":3829,"totalTrials":367,"cells":3830},"Endotoxin",{"EARLY_PHASE1":3831,"PHASE1":3833,"PHASE2":3835,"PHASE3":3837,"PHASE4":3839,"NA":3841},{"trials":3832,"activeCount":99},[],{"trials":3834,"activeCount":99},[],{"trials":3836,"activeCount":99},[],{"trials":3838,"activeCount":99},[],{"trials":3840,"activeCount":99},[],{"trials":3842,"activeCount":99},[3843,3855],{"nctId":3844,"briefTitle":3845,"status":333,"phases":3846,"primaryCompletion":793,"completion":3847,"start":2886,"enrollment":3848,"conditions":3849,"interventions":3852},"NCT00943267","Effect of Intrapulmonary Recombinant Human Activated Protein C (APC) on Coagulation and Inflammation After Lipopolysaccharide (LPS)",[92],"2011-03",52,[3850,3851],"Pneumonia","Lipopolysaccharides",[3853,3854,3829],"Drotrecogin alpha","Saline",{"nctId":3856,"briefTitle":3857,"status":333,"phases":3858,"primaryCompletion":3792,"completion":3792,"start":3859,"enrollment":3860,"conditions":3861,"interventions":3863},"NCT02127749","The Role of the Gut Microbiota in the Systemic Immune Response During Human Endotoxemia",[92],"2014-06",16,[3862],"Endotoxemia",[3829,3864],"Vancomycin, Metronidazole, Ciprofloxacin",{"intervention":3866,"totalTrials":367,"cells":3867},"Bezafibrate",{"EARLY_PHASE1":3868,"PHASE1":3870,"PHASE2":3872,"PHASE3":3874,"PHASE4":3888,"NA":3890},{"trials":3869,"activeCount":99},[],{"trials":3871,"activeCount":99},[],{"trials":3873,"activeCount":99},[],{"trials":3875,"activeCount":99},[3876],{"nctId":3877,"briefTitle":3878,"status":765,"phases":3879,"primaryCompletion":2952,"completion":3880,"start":3881,"enrollment":3882,"conditions":3883,"interventions":3887},"NCT02701166","The Effect of Bezafibrate on Cholestatic Itch",[90],"2018-04","2016-02",84,[3884,3885,3886],"Primary Biliary Cholangitis","Primary Sclerosing Cholangitis","Secondary Sclerosing Cholangitis",[3866],{"trials":3889,"activeCount":99},[],{"trials":3891,"activeCount":99},[3892],{"nctId":3893,"briefTitle":3894,"status":333,"phases":3895,"primaryCompletion":794,"completion":794,"start":3896,"enrollment":16,"conditions":3897,"interventions":3900},"NCT01165060","The Effect of Bezafibrate on the Level of Very Long Chain Fatty Acids (VLCFA) in X-linked Adrenoleukodystrophy (X-ALD)",[92],"2010-07",[3898,3899],"X-linked Adrenoleukodystrophy","Adrenomyeloneuropathy",[3866],{"intervention":3728,"totalTrials":367,"cells":3902},{"EARLY_PHASE1":3903,"PHASE1":3905,"PHASE2":3907,"PHASE3":3909,"PHASE4":3911,"NA":3913},{"trials":3904,"activeCount":99},[],{"trials":3906,"activeCount":99},[],{"trials":3908,"activeCount":99},[],{"trials":3910,"activeCount":99},[],{"trials":3912,"activeCount":99},[],{"trials":3914,"activeCount":99},[3915,3922],{"nctId":3916,"briefTitle":3917,"status":333,"phases":3918,"primaryCompletion":3859,"completion":3859,"start":3323,"enrollment":1510,"conditions":3919,"interventions":3921},"NCT01995084","In Vivo Assessment of Hypoxia in Gastro-intestinal Cancer Using 18F-HX4-PET: an Optimization and Reproducibility Study",[92],[3142,18,3920],"Rectal Cancer",[3728],{"nctId":3721,"briefTitle":3722,"status":333,"phases":3923,"primaryCompletion":2295,"completion":2295,"start":3724,"enrollment":420,"conditions":3924,"interventions":3925},[92],[3142],[3727,3728,3691],{"intervention":3927,"totalTrials":367,"cells":3928},"Acetazolamide",{"EARLY_PHASE1":3929,"PHASE1":3931,"PHASE2":3933,"PHASE3":3945,"PHASE4":3947,"NA":3949},{"trials":3930,"activeCount":99},[],{"trials":3932,"activeCount":99},[],{"trials":3934,"activeCount":99},[3935],{"nctId":3936,"briefTitle":3937,"status":333,"phases":3938,"primaryCompletion":3939,"completion":3939,"start":3940,"enrollment":3941,"conditions":3942,"interventions":3944},"NCT06114537","The AXIS Study: the Efficacy of Acetazolamide for the Treatment of Cystoid Fluid Collections in Retinoschisis",[89],"2024-09-13","2023-01-20",19,[3943],"Retinoschisis",[3927],{"trials":3946,"activeCount":99},[],{"trials":3948,"activeCount":99},[],{"trials":3950,"activeCount":99},[3951],{"nctId":3952,"briefTitle":3953,"status":765,"phases":3954,"primaryCompletion":3237,"completion":2295,"start":3955,"enrollment":1451,"conditions":3956,"interventions":3957},"NCT02824406","Cerebrovascular Reserve Measurements in Sickle Cell Disease",[],"2014-08",[21],[3927],{"intervention":3727,"totalTrials":367,"cells":3959},{"EARLY_PHASE1":3960,"PHASE1":3962,"PHASE2":3964,"PHASE3":3966,"PHASE4":3968,"NA":3970},{"trials":3961,"activeCount":99},[],{"trials":3963,"activeCount":99},[],{"trials":3965,"activeCount":99},[],{"trials":3967,"activeCount":99},[],{"trials":3969,"activeCount":99},[],{"trials":3971,"activeCount":99},[3972,3979],{"nctId":3973,"briefTitle":3974,"status":333,"phases":3975,"primaryCompletion":3409,"completion":3409,"start":1984,"enrollment":3976,"conditions":3977,"interventions":3978},"NCT01995240","Functional Magnetic Resonance Imaging of Pancreatic Cancer: a Feasibility and Reproducibility Study",[92],23,[3142],[3727],{"nctId":3721,"briefTitle":3722,"status":333,"phases":3980,"primaryCompletion":2295,"completion":2295,"start":3724,"enrollment":420,"conditions":3981,"interventions":3982},[92],[3142],[3727,3728,3691],{"intervention":3984,"totalTrials":95,"cells":3985},"acetylcysteine and salbutamol",{"EARLY_PHASE1":3986,"PHASE1":3988,"PHASE2":3990,"PHASE3":3992,"PHASE4":3994,"NA":3996},{"trials":3987,"activeCount":99},[],{"trials":3989,"activeCount":99},[],{"trials":3991,"activeCount":99},[],{"trials":3993,"activeCount":99},[],{"trials":3995,"activeCount":99},[],{"trials":3997,"activeCount":99},[3998],{"nctId":3999,"briefTitle":4000,"status":333,"phases":4001,"primaryCompletion":3164,"completion":3237,"start":4002,"enrollment":4003,"conditions":4004,"interventions":4006},"NCT02159196","Effectiveness of Routine Nebulization of Mucolytics and Bronchodilators During Mechanical Ventilation",[92],"2014-07",950,[4005],"Respiratory Failure",[3984,4007,4008],"acetylcysteine","salbutamol",{"intervention":4007,"totalTrials":95,"cells":4010},{"EARLY_PHASE1":4011,"PHASE1":4013,"PHASE2":4015,"PHASE3":4017,"PHASE4":4019,"NA":4021},{"trials":4012,"activeCount":99},[],{"trials":4014,"activeCount":99},[],{"trials":4016,"activeCount":99},[],{"trials":4018,"activeCount":99},[],{"trials":4020,"activeCount":99},[],{"trials":4022,"activeCount":99},[4023],{"nctId":3999,"briefTitle":4000,"status":333,"phases":4024,"primaryCompletion":3164,"completion":3237,"start":4002,"enrollment":4003,"conditions":4025,"interventions":4026},[92],[4005],[3984,4007,4008],{"intervention":4008,"totalTrials":95,"cells":4028},{"EARLY_PHASE1":4029,"PHASE1":4031,"PHASE2":4033,"PHASE3":4035,"PHASE4":4037,"NA":4039},{"trials":4030,"activeCount":99},[],{"trials":4032,"activeCount":99},[],{"trials":4034,"activeCount":99},[],{"trials":4036,"activeCount":99},[],{"trials":4038,"activeCount":99},[],{"trials":4040,"activeCount":99},[4041],{"nctId":3999,"briefTitle":4000,"status":333,"phases":4042,"primaryCompletion":3164,"completion":3237,"start":4002,"enrollment":4003,"conditions":4043,"interventions":4044},[92],[4005],[3984,4007,4008],{"intervention":4046,"totalTrials":95,"cells":4047},"casirivimab with imdevimab",{"EARLY_PHASE1":4048,"PHASE1":4050,"PHASE2":4052,"PHASE3":4054,"PHASE4":4056,"NA":4058},{"trials":4049,"activeCount":99},[],{"trials":4051,"activeCount":99},[],{"trials":4053,"activeCount":99},[],{"trials":4055,"activeCount":99},[],{"trials":4057,"activeCount":99},[],{"trials":4059,"activeCount":99},[4060],{"nctId":4061,"briefTitle":4062,"status":333,"phases":4063,"primaryCompletion":290,"completion":290,"start":4064,"enrollment":4065,"conditions":4066,"interventions":4068},"NCT05195060","TURN-COVID Biobank: The Dutch Cohort Study for the Evaluation of the Use of Neutralizing Monoclonal Antibodies and Other Antiviral Agents Against SARS-CoV-2",[],"2021-12-14",1178,[4067],"COVID-19",[4046,4069,4070],"sotrovimab","molnupiravir",{"intervention":4069,"totalTrials":95,"cells":4072},{"EARLY_PHASE1":4073,"PHASE1":4075,"PHASE2":4077,"PHASE3":4079,"PHASE4":4081,"NA":4083},{"trials":4074,"activeCount":99},[],{"trials":4076,"activeCount":99},[],{"trials":4078,"activeCount":99},[],{"trials":4080,"activeCount":99},[],{"trials":4082,"activeCount":99},[],{"trials":4084,"activeCount":99},[4085],{"nctId":4061,"briefTitle":4062,"status":333,"phases":4086,"primaryCompletion":290,"completion":290,"start":4064,"enrollment":4065,"conditions":4087,"interventions":4088},[],[4067],[4046,4069,4070],{"intervention":4070,"totalTrials":95,"cells":4090},{"EARLY_PHASE1":4091,"PHASE1":4093,"PHASE2":4095,"PHASE3":4097,"PHASE4":4099,"NA":4101},{"trials":4092,"activeCount":99},[],{"trials":4094,"activeCount":99},[],{"trials":4096,"activeCount":99},[],{"trials":4098,"activeCount":99},[],{"trials":4100,"activeCount":99},[],{"trials":4102,"activeCount":99},[4103],{"nctId":4061,"briefTitle":4062,"status":333,"phases":4104,"primaryCompletion":290,"completion":290,"start":4064,"enrollment":4065,"conditions":4105,"interventions":4106},[],[4067],[4046,4069,4070],{"intervention":4108,"totalTrials":95,"cells":4109},"Alemtuzumab Injection [Campath]",{"EARLY_PHASE1":4110,"PHASE1":4112,"PHASE2":4114,"PHASE3":4116,"PHASE4":4118,"NA":4120},{"trials":4111,"activeCount":99},[],{"trials":4113,"activeCount":99},[],{"trials":4115,"activeCount":99},[],{"trials":4117,"activeCount":99},[],{"trials":4119,"activeCount":99},[],{"trials":4121,"activeCount":99},[4122],{"nctId":4123,"briefTitle":4124,"status":765,"phases":4125,"primaryCompletion":4126,"completion":4127,"start":4128,"enrollment":2832,"conditions":4129,"interventions":4130},"NCT05905770","Do Alemtuzumab Levels Predict T Cell Chimerism After MSD SCT for SCD?",[],"2024-11","2025-11","2022-07-15",[21],[4108],{"intervention":3853,"totalTrials":95,"cells":4132},{"EARLY_PHASE1":4133,"PHASE1":4135,"PHASE2":4137,"PHASE3":4139,"PHASE4":4141,"NA":4143},{"trials":4134,"activeCount":99},[],{"trials":4136,"activeCount":99},[],{"trials":4138,"activeCount":99},[],{"trials":4140,"activeCount":99},[],{"trials":4142,"activeCount":99},[],{"trials":4144,"activeCount":99},[4145],{"nctId":3844,"briefTitle":3845,"status":333,"phases":4146,"primaryCompletion":793,"completion":3847,"start":2886,"enrollment":3848,"conditions":4147,"interventions":4148},[92],[3850,3851],[3853,3854,3829],{"intervention":3854,"totalTrials":95,"cells":4150},{"EARLY_PHASE1":4151,"PHASE1":4153,"PHASE2":4155,"PHASE3":4157,"PHASE4":4159,"NA":4161},{"trials":4152,"activeCount":99},[],{"trials":4154,"activeCount":99},[],{"trials":4156,"activeCount":99},[],{"trials":4158,"activeCount":99},[],{"trials":4160,"activeCount":99},[],{"trials":4162,"activeCount":99},[4163],{"nctId":3844,"briefTitle":3845,"status":333,"phases":4164,"primaryCompletion":793,"completion":3847,"start":2886,"enrollment":3848,"conditions":4165,"interventions":4166},[92],[3850,3851],[3853,3854,3829],{"intervention":4168,"totalTrials":95,"cells":4169},"Qutenza",{"EARLY_PHASE1":4170,"PHASE1":4172,"PHASE2":4174,"PHASE3":4176,"PHASE4":4178,"NA":4180},{"trials":4171,"activeCount":99},[],{"trials":4173,"activeCount":99},[],{"trials":4175,"activeCount":99},[],{"trials":4177,"activeCount":99},[],{"trials":4179,"activeCount":99},[],{"trials":4181,"activeCount":99},[4182],{"nctId":4183,"briefTitle":4184,"status":765,"phases":4185,"primaryCompletion":64,"completion":262,"start":4186,"enrollment":4187,"conditions":4188,"interventions":4192},"NCT05560516","Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)",[92],"2022-12-01",102,[4168,4189,4190,4191],"Duloxetine","Chemotherapy-induced Peripheral Neuropathy","CIPN - Chemotherapy-Induced Peripheral Neuropathy",[4168,4189],{"intervention":4189,"totalTrials":95,"cells":4194},{"EARLY_PHASE1":4195,"PHASE1":4197,"PHASE2":4199,"PHASE3":4201,"PHASE4":4203,"NA":4205},{"trials":4196,"activeCount":99},[],{"trials":4198,"activeCount":99},[],{"trials":4200,"activeCount":99},[],{"trials":4202,"activeCount":99},[],{"trials":4204,"activeCount":99},[],{"trials":4206,"activeCount":99},[4207],{"nctId":4183,"briefTitle":4184,"status":765,"phases":4208,"primaryCompletion":64,"completion":262,"start":4186,"enrollment":4187,"conditions":4209,"interventions":4210},[92],[4168,4189,4190,4191],[4168,4189],{"intervention":4212,"totalTrials":95,"cells":4213},"BMS + Bone Marrow Aspirate Concentrate",{"EARLY_PHASE1":4214,"PHASE1":4216,"PHASE2":4218,"PHASE3":4220,"PHASE4":4222,"NA":4224},{"trials":4215,"activeCount":99},[],{"trials":4217,"activeCount":99},[],{"trials":4219,"activeCount":99},[],{"trials":4221,"activeCount":99},[],{"trials":4223,"activeCount":99},[],{"trials":4225,"activeCount":99},[4226],{"nctId":4227,"briefTitle":4228,"status":765,"phases":4229,"primaryCompletion":4230,"completion":4231,"start":4232,"enrollment":2808,"conditions":4233,"interventions":4235},"NCT04475341","Osteochondral Lesions Under 15mm2 of the Talus; is Iliac Crest Bone Marrow Aspirate Concentrate the Key to Success?",[92],"2024-09-01","2024-09-02","2020-09-01",[4234],"Osteochondral Lesion of Talus",[4212],{"intervention":4237,"totalTrials":95,"cells":4238},"Sitagliptin",{"EARLY_PHASE1":4239,"PHASE1":4241,"PHASE2":4243,"PHASE3":4245,"PHASE4":4247,"NA":4249},{"trials":4240,"activeCount":99},[],{"trials":4242,"activeCount":99},[],{"trials":4244,"activeCount":99},[],{"trials":4246,"activeCount":99},[],{"trials":4248,"activeCount":99},[],{"trials":4250,"activeCount":99},[4251],{"nctId":4252,"briefTitle":4253,"status":333,"phases":4254,"primaryCompletion":2534,"completion":4255,"start":3847,"enrollment":3860,"conditions":4256,"interventions":4259},"NCT01272583","Dipeptidyl Peptidase-4 Inhibitors and Alpha-cell Recovery",[92],"2012-10",[4257,4258],"Type 1 Diabetes","Hypoglycemia",[4237],{"intervention":4261,"totalTrials":95,"cells":4262},"misoprostol",{"EARLY_PHASE1":4263,"PHASE1":4265,"PHASE2":4267,"PHASE3":4269,"PHASE4":4271,"NA":4273},{"trials":4264,"activeCount":99},[],{"trials":4266,"activeCount":99},[],{"trials":4268,"activeCount":99},[],{"trials":4270,"activeCount":99},[],{"trials":4272,"activeCount":99},[],{"trials":4274,"activeCount":99},[4275],{"nctId":4276,"briefTitle":4277,"status":333,"phases":4278,"primaryCompletion":4279,"completion":4280,"start":4281,"enrollment":4282,"conditions":4283,"interventions":4285},"NCT00945997","Misoprostol for Second Trimester Termination of Pregnancy",[92],"2004-09","2005-03","2000-10",176,[4284],"Termination of Pregnancy Second Trimester",[4261,4261],{"intervention":4287,"totalTrials":95,"cells":4288},"Atorvastatin 40 Mg Oral",{"EARLY_PHASE1":4289,"PHASE1":4291,"PHASE2":4293,"PHASE3":4295,"PHASE4":4297,"NA":4299},{"trials":4290,"activeCount":99},[],{"trials":4292,"activeCount":99},[],{"trials":4294,"activeCount":99},[],{"trials":4296,"activeCount":99},[],{"trials":4298,"activeCount":99},[],{"trials":4300,"activeCount":99},[4301],{"nctId":4302,"briefTitle":4303,"status":333,"phases":4304,"primaryCompletion":4305,"completion":4305,"start":2652,"enrollment":3071,"conditions":4306,"interventions":4308},"NCT05730634","The Effect of Statin Treatment on Arterial Wall Inflammation as Assessed With 68Ga-DOTATATE PET-CT",[92],"2022-05-06",[1512,4307],"Vascular Inflammation",[4287],{"intervention":4310,"totalTrials":95,"cells":4311},"Phenylephrine",{"EARLY_PHASE1":4312,"PHASE1":4314,"PHASE2":4316,"PHASE3":4318,"PHASE4":4320,"NA":4322},{"trials":4313,"activeCount":99},[],{"trials":4315,"activeCount":99},[],{"trials":4317,"activeCount":99},[],{"trials":4319,"activeCount":99},[],{"trials":4321,"activeCount":99},[],{"trials":4323,"activeCount":99},[4324],{"nctId":4325,"briefTitle":4326,"status":333,"phases":4327,"primaryCompletion":4328,"completion":4328,"start":1132,"enrollment":2113,"conditions":4329,"interventions":4331},"NCT03816072","Quantification of Dynamic and Static Cerebral Autoregulation (CA) Under Anaesthesia",[92],"2019-09-23",[4330],"Cerebrovascular Circulation",[4310,4332,4333],"Propofol","Sevoflurane",{"intervention":4332,"totalTrials":95,"cells":4335},{"EARLY_PHASE1":4336,"PHASE1":4338,"PHASE2":4340,"PHASE3":4342,"PHASE4":4344,"NA":4346},{"trials":4337,"activeCount":99},[],{"trials":4339,"activeCount":99},[],{"trials":4341,"activeCount":99},[],{"trials":4343,"activeCount":99},[],{"trials":4345,"activeCount":99},[],{"trials":4347,"activeCount":99},[4348],{"nctId":4325,"briefTitle":4326,"status":333,"phases":4349,"primaryCompletion":4328,"completion":4328,"start":1132,"enrollment":2113,"conditions":4350,"interventions":4351},[92],[4330],[4310,4332,4333],{"intervention":4333,"totalTrials":95,"cells":4353},{"EARLY_PHASE1":4354,"PHASE1":4356,"PHASE2":4358,"PHASE3":4360,"PHASE4":4362,"NA":4364},{"trials":4355,"activeCount":99},[],{"trials":4357,"activeCount":99},[],{"trials":4359,"activeCount":99},[],{"trials":4361,"activeCount":99},[],{"trials":4363,"activeCount":99},[],{"trials":4365,"activeCount":99},[4366],{"nctId":4325,"briefTitle":4326,"status":333,"phases":4367,"primaryCompletion":4328,"completion":4328,"start":1132,"enrollment":2113,"conditions":4368,"interventions":4369},[92],[4330],[4310,4332,4333],{"intervention":4371,"totalTrials":95,"cells":4372},"Belimumab",{"EARLY_PHASE1":4373,"PHASE1":4375,"PHASE2":4377,"PHASE3":4379,"PHASE4":4381,"NA":4383},{"trials":4374,"activeCount":99},[],{"trials":4376,"activeCount":99},[],{"trials":4378,"activeCount":99},[],{"trials":4380,"activeCount":99},[],{"trials":4382,"activeCount":99},[],{"trials":4384,"activeCount":99},[4385],{"nctId":4386,"briefTitle":4387,"status":765,"phases":4388,"primaryCompletion":69,"completion":4389,"start":4390,"enrollment":3434,"conditions":4391,"interventions":4393},"NCT06327724","Belimumab in SLE Synovial Inflammation and Lymph Nodes",[],"2025-03-01","2023-09-01",[4392],"Systemic Lupus Erythematosus",[4371],{"intervention":4395,"totalTrials":95,"cells":4396},"WES and WGS",{"EARLY_PHASE1":4397,"PHASE1":4399,"PHASE2":4401,"PHASE3":4403,"PHASE4":4405,"NA":4407},{"trials":4398,"activeCount":99},[],{"trials":4400,"activeCount":99},[],{"trials":4402,"activeCount":99},[],{"trials":4404,"activeCount":99},[],{"trials":4406,"activeCount":99},[],{"trials":4408,"activeCount":99},[4409],{"nctId":4410,"briefTitle":4411,"status":333,"phases":4412,"primaryCompletion":4413,"completion":4413,"start":4414,"enrollment":4415,"conditions":4416,"interventions":4418},"NCT06200142","Zoektocht Naar Erfelijke MetaBole Aandoening (Dutch)\u002F Solve The Unsolved (English)",[92],"2021-12-31","2019-12-10",334,[4417],"Inherited Metabolic Disorders",[4395],{"intervention":4420,"totalTrials":95,"cells":4421},"Ferumoxytol",{"EARLY_PHASE1":4422,"PHASE1":4424,"PHASE2":4426,"PHASE3":4428,"PHASE4":4430,"NA":4432},{"trials":4423,"activeCount":99},[],{"trials":4425,"activeCount":99},[],{"trials":4427,"activeCount":99},[],{"trials":4429,"activeCount":99},[],{"trials":4431,"activeCount":99},[],{"trials":4433,"activeCount":99},[4434],{"nctId":4435,"briefTitle":4436,"status":333,"phases":4437,"primaryCompletion":4438,"completion":4438,"start":4439,"enrollment":361,"conditions":4440,"interventions":4441},"NCT02253602","Innovative MRI Techniques to Improve Treatment Stratification of Patients With Esophageal Cancer",[92],"2018-05","2014-09",[422],[4420],{"intervention":3719,"totalTrials":95,"cells":4443},{"EARLY_PHASE1":4444,"PHASE1":4446,"PHASE2":4448,"PHASE3":4450,"PHASE4":4452,"NA":4454},{"trials":4445,"activeCount":99},[],{"trials":4447,"activeCount":99},[],{"trials":4449,"activeCount":99},[],{"trials":4451,"activeCount":99},[],{"trials":4453,"activeCount":99},[],{"trials":4455,"activeCount":99},[4456],{"nctId":3710,"briefTitle":3711,"status":765,"phases":4457,"primaryCompletion":2414,"completion":3713,"start":3714,"enrollment":3715,"conditions":4458,"interventions":4459},[92],[1260],[3718,3719,3691],{"intervention":4461,"totalTrials":95,"cells":4462},"Time Restricted Eating",{"EARLY_PHASE1":4463,"PHASE1":4465,"PHASE2":4467,"PHASE3":4469,"PHASE4":4471,"NA":4473},{"trials":4464,"activeCount":99},[],{"trials":4466,"activeCount":99},[],{"trials":4468,"activeCount":99},[],{"trials":4470,"activeCount":99},[],{"trials":4472,"activeCount":99},[],{"trials":4474,"activeCount":99},[4475],{"nctId":4476,"briefTitle":4477,"status":765,"phases":4478,"primaryCompletion":4479,"completion":4480,"start":4481,"enrollment":3071,"conditions":4482,"interventions":4487},"NCT05898360","Promoting Immune Health by Intermittent Fasting: a Pilot Study",[92],"2024-02-27","2024-06-30","2023-05-15",[4483,4484,4485,4486,643],"Metabolic Syndrome","HEALTHY VOLUNTEERS","Time Restricted Feeding","Insulin Resistance",[4461],{"intervention":4489,"totalTrials":95,"cells":4490},"Decitabine",{"EARLY_PHASE1":4491,"PHASE1":4493,"PHASE2":4495,"PHASE3":4497,"PHASE4":4499,"NA":4501},{"trials":4492,"activeCount":99},[],{"trials":4494,"activeCount":99},[],{"trials":4496,"activeCount":99},[],{"trials":4498,"activeCount":99},[],{"trials":4500,"activeCount":99},[],{"trials":4502,"activeCount":99},[4503],{"nctId":4504,"briefTitle":4505,"status":1578,"phases":4506,"primaryCompletion":3046,"completion":3046,"start":4507,"enrollment":16,"conditions":4508,"interventions":4510},"NCT01882660","Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study",[92],"2013-07",[4509],"Colon Cancer",[4489],{"intervention":4512,"totalTrials":95,"cells":4513},"Rotavirus vaccine, Tetanus vaccine and Pneumococcal vaccine",{"EARLY_PHASE1":4514,"PHASE1":4516,"PHASE2":4518,"PHASE3":4520,"PHASE4":4522,"NA":4524},{"trials":4515,"activeCount":99},[],{"trials":4517,"activeCount":99},[],{"trials":4519,"activeCount":99},[],{"trials":4521,"activeCount":99},[],{"trials":4523,"activeCount":99},[],{"trials":4525,"activeCount":99},[4526],{"nctId":4527,"briefTitle":4528,"status":333,"phases":4529,"primaryCompletion":4530,"completion":3409,"start":3387,"enrollment":4531,"conditions":4532,"interventions":4538},"NCT02538211","The Role of the Intestinal Microbiome in Enteric and Systemic Vaccine Immune Responses",[92],"2017-01",63,[4533,4534,4535,4536,4537],"Rotavirus Infections","Intestinal Bacteria Flora Disturbance","Reaction - Vaccine Nos","Tetanus","Streptococcal Pneumonia",[4512],{"intervention":4540,"totalTrials":95,"cells":4541},"Absence of vitamin K antagonist",{"EARLY_PHASE1":4542,"PHASE1":4544,"PHASE2":4546,"PHASE3":4548,"PHASE4":4550,"NA":4552},{"trials":4543,"activeCount":99},[],{"trials":4545,"activeCount":99},[],{"trials":4547,"activeCount":99},[],{"trials":4549,"activeCount":99},[],{"trials":4551,"activeCount":99},[],{"trials":4553,"activeCount":99},[4554],{"nctId":4555,"briefTitle":4556,"status":1578,"phases":4557,"primaryCompletion":1629,"completion":4558,"start":4559,"enrollment":785,"conditions":4560,"interventions":4562},"NCT01556659","LV Thrombus After Acute AMI: A Randomized Controlled Trial",[92],"2022-06","2012-03",[4561],"Ventricular Thrombosis Mural Following Myocardial Infarction",[4540],{"intervention":4564,"totalTrials":95,"cells":4565},"Oral Impact",{"EARLY_PHASE1":4566,"PHASE1":4568,"PHASE2":4570,"PHASE3":4572,"PHASE4":4574,"NA":4576},{"trials":4567,"activeCount":99},[],{"trials":4569,"activeCount":99},[],{"trials":4571,"activeCount":99},[],{"trials":4573,"activeCount":99},[],{"trials":4575,"activeCount":99},[],{"trials":4577,"activeCount":99},[4578],{"nctId":4579,"briefTitle":4580,"status":333,"phases":4581,"completion":4582,"start":4583,"conditions":4584,"interventions":4588},"NCT00247793","Immunonutrition in Cardiac Surgery",[92],"1998-12","1996-07",[4585,4586,4587],"Thoracic Surgery","Cardiac Surgery","Cardiopulmonary Bypass",[4564],{"intervention":4590,"totalTrials":95,"cells":4591},"Engerix-B",{"EARLY_PHASE1":4592,"PHASE1":4594,"PHASE2":4596,"PHASE3":4598,"PHASE4":4600,"NA":4602},{"trials":4593,"activeCount":99},[],{"trials":4595,"activeCount":99},[],{"trials":4597,"activeCount":99},[],{"trials":4599,"activeCount":99},[],{"trials":4601,"activeCount":99},[],{"trials":4603,"activeCount":99},[4604],{"nctId":4605,"briefTitle":4606,"status":765,"phases":4607,"primaryCompletion":3629,"completion":4608,"start":4609,"enrollment":237,"conditions":4610,"interventions":4611},"NCT05200338","Preservation and Transfer of HBV Immunity After Allogeneic HSCT for SCD",[92],"2024-12","2021-06-08",[21],[4590],{"intervention":4613,"totalTrials":95,"cells":4614},"Biological Drug",{"EARLY_PHASE1":4615,"PHASE1":4617,"PHASE2":4619,"PHASE3":4621,"PHASE4":4623,"NA":4625},{"trials":4616,"activeCount":99},[],{"trials":4618,"activeCount":99},[],{"trials":4620,"activeCount":99},[],{"trials":4622,"activeCount":99},[],{"trials":4624,"activeCount":99},[],{"trials":4626,"activeCount":99},[4627],{"nctId":4628,"briefTitle":4629,"status":765,"phases":4630,"primaryCompletion":3022,"completion":3022,"start":4631,"enrollment":888,"conditions":4632,"interventions":4633},"NCT06024707","Fluctuation Analyses of Asthma Patients With Biologics Use",[],"2023-12",[2603],[4613],{"intervention":4635,"totalTrials":95,"cells":4636},"Peg-Interferon alfa 2a + Adefovir dipivoxil, Peg-Interferon alfa 2a + Tenofovir disoproxil fumarate",{"EARLY_PHASE1":4637,"PHASE1":4639,"PHASE2":4641,"PHASE3":4643,"PHASE4":4645,"NA":4647},{"trials":4638,"activeCount":99},[],{"trials":4640,"activeCount":99},[],{"trials":4642,"activeCount":99},[],{"trials":4644,"activeCount":99},[],{"trials":4646,"activeCount":99},[],{"trials":4648,"activeCount":99},[4649],{"nctId":4650,"briefTitle":4651,"status":333,"phases":4652,"primaryCompletion":418,"completion":418,"start":1604,"enrollment":2013,"conditions":4653,"interventions":4655},"NCT00973219","Hepatitis B Surface Antigen(HBsAg) Loss in Chronic Hepatitis B Patients With Low Viral Load",[92],[4654],"Chronic Hepatitis B",[4635],{"intervention":4657,"totalTrials":95,"cells":4658},"Digital consult",{"EARLY_PHASE1":4659,"PHASE1":4661,"PHASE2":4663,"PHASE3":4665,"PHASE4":4667,"NA":4669},{"trials":4660,"activeCount":99},[],{"trials":4662,"activeCount":99},[],{"trials":4664,"activeCount":99},[],{"trials":4666,"activeCount":99},[],{"trials":4668,"activeCount":99},[],{"trials":4670,"activeCount":99},[4671],{"nctId":4672,"briefTitle":4673,"status":333,"phases":4674,"primaryCompletion":4675,"completion":4675,"start":3823,"enrollment":4676,"conditions":4677,"interventions":4679},"NCT05413447","Assessment of Digital Consultations on Clinical Impact and Efficiency",[92],"2024-06-06",150,[4678],"Heart Failure",[4657],{"intervention":4681,"totalTrials":95,"cells":4682},"ADRB2-genotype guided treatment",{"EARLY_PHASE1":4683,"PHASE1":4685,"PHASE2":4687,"PHASE3":4689,"PHASE4":4691,"NA":4693},{"trials":4684,"activeCount":99},[],{"trials":4686,"activeCount":99},[],{"trials":4688,"activeCount":99},[],{"trials":4690,"activeCount":99},[],{"trials":4692,"activeCount":99},[],{"trials":4694,"activeCount":99},[4695],{"nctId":4696,"briefTitle":4697,"status":333,"phases":4698,"primaryCompletion":4699,"completion":4699,"start":4700,"enrollment":4187,"conditions":4701,"interventions":4703},"NCT03654508","Pharmacogenetics Use For Further Treatment Improvement in childreN",[92],"2023-10-18","2018-06-12",[4702],"Asthma in Children",[4681],{"intervention":4705,"totalTrials":95,"cells":4706},"Liraglutide",{"EARLY_PHASE1":4707,"PHASE1":4709,"PHASE2":4711,"PHASE3":4713,"PHASE4":4715,"NA":4717},{"trials":4708,"activeCount":99},[],{"trials":4710,"activeCount":99},[],{"trials":4712,"activeCount":99},[],{"trials":4714,"activeCount":99},[],{"trials":4716,"activeCount":99},[],{"trials":4718,"activeCount":99},[4719],{"nctId":4720,"briefTitle":4721,"status":333,"phases":4722,"primaryCompletion":4530,"completion":4530,"start":3410,"enrollment":4676,"conditions":4723,"interventions":4725},"NCT02036372","Perioperative Insulin, GIK or GLP-1 Treatment in Diabetes Mellitus",[92],[4724],"Diabetes Mellitus Type II",[4705,4726,4727],"Insulin bolus","GIK",{"intervention":4726,"totalTrials":95,"cells":4729},{"EARLY_PHASE1":4730,"PHASE1":4732,"PHASE2":4734,"PHASE3":4736,"PHASE4":4738,"NA":4740},{"trials":4731,"activeCount":99},[],{"trials":4733,"activeCount":99},[],{"trials":4735,"activeCount":99},[],{"trials":4737,"activeCount":99},[],{"trials":4739,"activeCount":99},[],{"trials":4741,"activeCount":99},[4742],{"nctId":4720,"briefTitle":4721,"status":333,"phases":4743,"primaryCompletion":4530,"completion":4530,"start":3410,"enrollment":4676,"conditions":4744,"interventions":4745},[92],[4724],[4705,4726,4727],{"intervention":4727,"totalTrials":95,"cells":4747},{"EARLY_PHASE1":4748,"PHASE1":4750,"PHASE2":4752,"PHASE3":4754,"PHASE4":4756,"NA":4758},{"trials":4749,"activeCount":99},[],{"trials":4751,"activeCount":99},[],{"trials":4753,"activeCount":99},[],{"trials":4755,"activeCount":99},[],{"trials":4757,"activeCount":99},[],{"trials":4759,"activeCount":99},[4760],{"nctId":4720,"briefTitle":4721,"status":333,"phases":4761,"primaryCompletion":4530,"completion":4530,"start":3410,"enrollment":4676,"conditions":4762,"interventions":4763},[92],[4724],[4705,4726,4727],{"intervention":3864,"totalTrials":95,"cells":4765},{"EARLY_PHASE1":4766,"PHASE1":4768,"PHASE2":4770,"PHASE3":4772,"PHASE4":4774,"NA":4776},{"trials":4767,"activeCount":99},[],{"trials":4769,"activeCount":99},[],{"trials":4771,"activeCount":99},[],{"trials":4773,"activeCount":99},[],{"trials":4775,"activeCount":99},[],{"trials":4777,"activeCount":99},[4778],{"nctId":3856,"briefTitle":3857,"status":333,"phases":4779,"primaryCompletion":3792,"completion":3792,"start":3859,"enrollment":3860,"conditions":4780,"interventions":4781},[92],[3862],[3829,3864]]